Journal of Experimental Biology and Agricultural Sciences

<http://www.jebas.org>

ISSN No. 2320 – 8694

PHARMACEUTICAL POTENTIAL OF LABORATORY GROWN CULTURES OF BLUE-GREEN ALGAE: A COMPREHENSIVE REVIEW AND FUTURE POSSIBILITIES

Ritu Chauhan¹, Abhishek Chauhan^{2*}, Ashutosh Tripathi^{1*}, Anuj Ranjan²,
Subhash C. Chauhan³, Tanu Jindal^{1,2}

¹Amity Institute of Environmental Sciences, Amity University, Sector-125, Noida, Uttar Pradesh, India

²Amity Institute of Environmental Toxicology, Safety and Management, Amity University, Sector-125, Noida, Uttar Pradesh, India

³STCECR, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA

Received – July 26, 2021; Revision – September 29, 2021; Accepted – October 16, 2021

Available Online – October 30, 2021

DOI: [http://dx.doi.org/10.18006/2021.9\(5\).543.571](http://dx.doi.org/10.18006/2021.9(5).543.571)

KEYWORDS

Blue-Green Algae

Biomass

Pharmaceutically Important
Compound

Biological activities

Discovery

Development

ABSTRACT

COVID-19 pandemic has taught the world researchers the urgent need for new sources and novel pharmaceuticals not only for existing diseases but also for both seasonal epidemics and future pandemics. Pharmaceutical drug discoveries for the past fifty years depended deeply on the procedure of empirical transmission of a huge number of pure bioactive compounds to provide new leads. The screening of extracts or isolating compounds is a common way to discover novel biologically active molecules. Most of the valuable Blue-Green algal metabolites are concentrated in their biomass. For existence in nature, Blue-Green algae (BGA) secrete and contain various organic substances like proteins, fatty acids, vitamins, pigments, primary and secondary metabolites, and these compounds are explored for potential biological activities such as antibacterial, antifungal, antiviral (including the anti-SARS-CoV-2 virus that causes COVID-19), anticancer, antioxidant, antidiabetic, protease inhibitory activity, anti-inflammatory activity, etc. Due to their diverse application, pharmaceutical companies have shown commercial interest in the Blue-green algal group for the discovery and development of novel molecules to combat deadly diseases for the benefit of society and mankind. The current review paper highlights and discusses the diverse pharmaceutical potential of laboratory-grown cultures of BGA along with comprehensive and current knowledge on bioactive compounds discovered by researchers globally.

* Corresponding author

E-mail: atripathi1@amity.edu (Ashutosh Tripathi); akchauhan@amity.edu (Abhishek Chauhan)

Peer review under responsibility of Journal of Experimental Biology and Agricultural Sciences.

Production and Hosting by Horizon Publisher India [HPI]
(<http://www.horizonpublisherindia.in/>).
All rights reserved.

All the articles published by [Journal of Experimental Biology and Agricultural Sciences](#) are licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](#) Based on a work at www.jebas.org.

1 Introduction

In the extremely competitive environment of current pharmaceutical research and development of new molecules, natural products offer a unique element of molecular diversity and biological functionality, which is essential for drug discovery (Bernardini et al., 2018; Chatterjee et al., 2019; Atanasov et al., 2021). The study of secondary metabolites that organisms such as microbes including BGA and plants have evolved, largely for their survival, has historically proved of immense benefit in drug discovery and development (Petersen et al., 2020). They are providing a rich source of structurally novel bioactive molecules such as lipopeptides, amino acids, fatty acids, etc., many of which have become life-saving drugs (Singh et al., 2021a). In recent decades, pharmaceutical inventions are focused on natural sources (microbial sources such as bacterial, fungi, algal including Blue-green algae) which can deal with recent diseases. Medicinal chemistry is the backbone of lead generation in early drug invention where small molecule hits from high throughput screen (HTS), which leads to limited optimization and identification of lead compounds (Jimenez-Lopez et al., 2021). Despite these efforts, some new chemical entities have reached the market, and researchers throughout the world now are giving more attention to exploring these groups of microorganisms (including microbes from extreme environments i.e., Arctic, Antarctic) for extractions of novel compounds with diverse pharmaceutical applications.

1.1 The need for novel Pharmaceutically important compounds

The less accessibility and high cost of new generation antibiotics necessitate looking for the substances from alternative medicines with claimed antimicrobial activity. Today, most of the diseases caused by pathogens can be cured with the help of available antibiotics, but the discovery of any new antibiotic generally follows up with a course of resistance mechanism building up against it among the target organisms (Dimri et al., 2018). This phenomenon is known as 'antibiotic resistance is developing among microbial species at an appreciable rate, is a formidable complication of prudent and overuse of available antibiotics, and is imposing a serious health threat to human welfare. World Health Organization (WHO) in February 2017 published a report of antimicrobial-resistant bacteria for which new pharmaceutical compounds are urgently needed (WHO, 2017). Keeping in view the urgent requirement, the current review highlights various important aspects about the pharmaceutical potential of laboratory-grown cultures of BGA.

1.2 Blue-Green Algae

Blue-green algae are a group of extraordinary, diverse, gram-negative, oxygenic, photosynthetic prokaryotic, microscopic oldest organisms that originated 3.5 billion years ago (Kaushik et al.,

2009). Blue-green algae are found all over the world, shows remarkable ecological diversity of habitats such as Freshwater (Khatoon et al., 2018; Chittapun et al., 2020), Terrestrial (Radzi et al., 2019; Riba et al., 2020), Marine (Basu et al., 2019; Uma et al., 2020), Hot spring (Tang et al., 2018; Cheng et al., 2020), etc. These BGA are also widely distributed in the polar region such as the Arctic, Antarctic, Southern Ocean, and Himalayas (Singh & Elster, 2007; Rego et al., 2019; Zaki et al., 2020). It has been estimated that about 2000 strains of freshwater and marine BGA are distributed all over the world. The capability to grow in adverse conditions and their autotrophic nature makes them an eligible candidate to grow in low nutrient-deficient lakes, ponds, and oceans which pose a serious threat to water and result in eutrophication. This may cause unpleasant tastes and odors of water through the secretion of volatile compounds. Random screening of blue-green algae will continue to play an important role in the drug discovery process for the foreseeable future. Several studies have been conducted for the isolation and identification of Blue-Green Algae from water, soil, sediments, algal mats, etc. (Figure 1-8) using advanced morphological, physiological, and molecular characterization techniques (Bellinger & Sigee, 2015; Hokmollahi et al., 2016; Radkova et al., 2020). These BGA have successfully grown on a laboratory scale using selective media i.e. BG-11, BG-13, Chu 10 (Chu, 1942; Rippka et al., 1979; Kaushik et al., 2010), Allen and Arnon Medium (Allen & Arnon, 1955), Fogg's Medium (Fogg's, 1965), Modified Bristol's Medium (Bold, 1949) and Pringsheim's Medium (Pringsheim, 1946). Blue-green algae do not require carbon or energy sources in their growth medium. Thus, they require only a basic inorganic medium, which has several logical advantages when performing the mass culture and purification of active compounds. Flask cultivation and mass cultivation for instance open pond system, hybrid system, closed photobioreactors are very well-known culturing methods used for generating biomass maintaining proper light, temperature, water, CO₂ supply, pH, nutrient supply, and proper mixing (Kaiwan-arporn et al., 2012; Troschl et al., 2017; Al-Saman et al., 2020; Jo et al., 2020). Lyophilization (freeze-drying), air drying, and sun-drying are some known popular techniques to convert biomass into powder (Smetana et al., 2017). Aqueous extraction i.e. cold and hot water extraction, organic extraction i.e. polar solvent extraction, semi-polar solvent extraction, non-polar solvent extraction, mix solvents extraction and sequential extractions, soxhlet extraction have been used extensively to isolate medicinal value active ingredients (Fatima et al., 2017; Vanlalveni et al., 2018; Yücer et al., 2018; Saurav et al., 2019). Generally, all blue-green algae vegetative cells contain carboxysomes, pseudocrystalline aggregates of the key enzymes of CO₂ fixation via the reductive pentose phosphate pathway and glycogen is a general carbohydrate reserve material of cyanobacteria. Other cellular inclusions include Poly- β -hydroxybutyrate (PHB) granules, cyanophycin granules, polyphosphate granules, carboxysomes or polyhedral bodies, and gas

vesicles (Stanier, 1988). They show notable ecological diversity. Because of extensive eutrophication of lakes, ponds and some parts of oceans BGA often forms blooms, which lead to water hygienic

problems (Chorus et al., 2000; Duy et al., 2000). They may cause unpleasant tastes and odors through the excretion of volatile compounds (Jones & Korth, 1995; Liu et al., 2006).

Figure 1 Laboratory Grown Culture of BGA (Medium: BG-11): A. *Calothrix* sp., B. *Spirulina* sp. C. *Oscillatoria* sp.

Figure 2 Microscopic images of *Anabaena* species (Chauhan & Jindal, 2020)

Figure 3 Microscopic images of *Nostoc* species (Chauhan & Jindal, 2020)

Figure 4 Microscopic images of *Calothrix* species (Chauhan & Jindal, 2020)

Figure 5 Microscopic images of *Oscillatoria* species (Chauhan & Jindal, 2020)

Figure 6 Microscopic images of *spirulina* species (Chauhan & Jindal, 2020)

Figure 7 Scanning Electron Micrograph (SEM) image of *Anabaena* sp. (A) and *Nostoc* sp. (B) as per Kaushik & Chauhan (2008a)

Figure 8 Scanning Electron Micrograph (SEM) image of *Spirulina platensis* (Kaushik & Chauhan, 2008b)

2 Pharmaceutical Potential of BGA

Blue-green algae are the rich source of structurally novel and biologically active metabolites with diverse antibacterial, antifungal, antiviral (including the anti-SARS-CoV-2 virus that causes COVID-19), anticancer, antioxidant, antidiabetic, protease inhibitory activity, anti-inflammatory activity, immunomodulatory activity, larvicide, and protease inhibitory activity, etc. (Figure 9) (Nainangu et al., 2020; Jafari et al., 2021). The first time before 1500 BC, medicinal and nutritional properties have been investigated for *Nostoc* algal species to treat gout, fistula, and cancer (Cardellina et al., 1979a; Shishido et al., 2020).

These photosynthetic microorganisms can yield proteins, carbohydrates, and lipids as a result of photosynthesis thus referred to as important biological resources having a wide range of biotechnological applications in the modern world due to their ability to grow rapidly even in harsh environmental conditions (Padmini et al., 2021). A search of these organisms for medicinal purposes has revealed important chemical prototypes for the finding of new agents, stimulating the use of refined physical techniques and new syntheses of molecules with the pharmaceutical application for human welfare. Phytochemical's constituents described from extracts of Blue-Green algae have been described by researchers (Figure 10) and are very well documented (Vasudevan et al., 2020; Nainangu et al., 2020; Gabr

et al., 2020; Vasudevan et al., 2020)

2.1 Pharmaceutically important compounds isolated from BGA

Secondary metabolites refer to those compounds that are not used by the organisms for their primary metabolisms. Secondary metabolites influence other organisms in the vicinity and are thought to be of phylogenetic importance (Carpine & Sieber, 2021). Secondary metabolites include several types of compounds that may act as hormones, antibiotics, allelochemicals, toxins, and biotoxins that are found in surface supplies of fresh water (Carmichael, 1992). The ability of such compounds to kill bacteria and fungi have been well documented (Bonjouklian et al., 1988). The properties of secondary metabolites in nature are not completely understood (Metting & Pyne, 1986; Inderjit & Dakshini, 1994; Vasudevan et al., 2020).

The blue-green algae bear the characteristics to secrete vitamins, amino acids, fatty acids, carbohydrates, and various primary and secondary metabolites like amines, histamines, histidine, tannins, terpenoids, bromophenol, and polysaccharides (Figure 11). Few of these compounds are proven to be biologically active (Metting & Pyne, 1986; Padmini et al., 2021). The recent examples are cyanovirin-N secreted by *Nostoc elliposporum* and anti-HIV glycolipids secreted by *Isochyros* and bromophenol are secreted by *Calothrix* sp. (Jaspars & Lawton 1998; Safari et al., 2020).

Figure 9 Pharmaceutical Potential of Blue-Green Algae

Figure 10 Major Phytochemicals constituents described from extracts of Blue-Green algae

Figure 11 Pharmaceutically Important Compounds isolated from BGA

2.1.1 Antibacterial Potential of BGA

BGA are known for the secretions of antibacterial compounds with potential antibacterial activity against both Gram-positive and Gram-negative bacteria. Several strains such as *Anabaena*, *Lyngbya*, *Calothrix*, *Spirulina*, *Nostoc*, *Hapalosiphone*, *Phormidium*, and *Oscillatoria* have been identified by researchers from different habitats which can produce a wide variety of antibacterial molecules having therapeutic potentials (Chauhan et al., 2022). These organisms are even being altered genetically using biotechnological interventions for the production of various active compounds having antibacterial activity such as Bacteriocin Ambigol A, Parsiguine, Hapalindole, Hormothamnin A. *Bacillus subtilis*, *Staphylococcus aureus*, *Streptococcus sanguinis*, *Pseudomonas aeruginosa*, *Escherichia coli*, *L. monocytogenes*, *Salmonella typhimurium*, *Enterobacter aerogenes*, *Klebsiella pneumonia*, *Methicillin-resistant B. anthracis* are the examples of some gram-positive and Gram-negative bacteria which have studied for the inhibitory action of BGA (Luesch et al., 2001; Muller et al., 2006; Mo et al., 2009; Sturdy et al., 2010). The first partly identified antimicrobial compound isolated from algae were obtained from unicellular green algae particularly, *Chlorella* which contained a substance termed as 'chlorellin' that exhibited inhibitory activity against both Gram-positive and Gram-negative bacteria, including *Staphylococcus aureus*, *Streptococcus pyogenes*, *Bacillus subtilis*, and *Pseudomonas aeruginosa* (Pratt et al., 1944). *Chlorellin* is composed of peroxides of unsaturated fatty acids (Spoehr & Milner, 1949). Kaushik &

Chauhan (2008a) had reported the antibacterial activity of several species of cyanobacteria such as *Anabaena*, *Lyngbya*, *Calothrix*, *Spirulina*, *Nostoc*, *Hapalosiphone*, *Phormidium*, and *Oscillatoria*, etc. against both Gram-positive (*Staphylococcus aureus*, *Bacillus subtilis*, *Bacillus cereus*, etc.) and Gram-negative bacteria (*Escherichia coli*, *Pseudomonas aeruginosa*, *Salmonella typhi*, etc.). In a similar study, various species of *Anabaena* were evaluated for their antimicrobial activity and active antibacterial extracts were further screened for the presence of various chemical constituents through HPTLC techniques (Kaushik et al., 2009; Chauhan et al., 2010). Extracts of *Nostoc commune* and *Lyngbya majuscula* were studied for potent antimicrobial activity against clinically significant microorganisms (Kaushik & Chauhan, 2008a; Kaushik & Chauhan 2008b; Kaushik et al., 2009; Verma et al., 2016). HPTLC analysis were also performed to identify novel pharmaceutical compounds responsible for the activity. In a recent study, El-Sheekh et al. (2021) have evaluated the antibacterial activity of *Oscillatoria* sp. and *Spirulina* mediated silver and gold nanoparticles. Two new antibacterial molecules namely Arachidonoyl dopamine and fluocinolone recently discovered from methanolic extracts of *Arthrospira platensis*, a BGA isolated from a hypersaline lake in Rajasthan, India (Singh et al., 2021b). In another study, Antibacterial efficacy extracts of *Oxynema thaianum* have been assessed against multi-drug-resistant bacteria such as *E. coli* and *K. pneumoniae* (Padmini et al., 2021). Antibacterial compounds discovered from various species of BGA have been listed in Table 1 and Figure 12.

Table 1 Antibacterial compounds reported from BGA

BGA Sps.	Antibacterial Compounds	Detail of Chemical compounds	References
<i>Scytonema pseudo hofmanni</i>	Scytophycins C	MF: C ₄₅ H ₇₅ NO ₁₁ MW: 806.1g/mol IUPAC Name: N-[(E,3R,4R,5R,9S,10S,11S)-10-hydroxy-11-[(1S,3S,4R,5S,7R,8S,9R,12E,14E,17S,19R)-17-hydroxy-3,5,7-trimethoxy-4,8,14-trimethyl-11-oxo-10,23-dioxabicyclo[17.3.1]tricos-12,14,20-trien-9-yl]-4-methoxy-3,5,9-trimethyl-6-oxododec-1-enyl]-N-methylformamide	Ishibashi et al., 1986
<i>Scytonema ocellatum</i> , <i>Tolypothrix conglutinate</i>	Tolytoxin	MF: C ₄₆ H ₇₅ NO ₁₃ MW: 850.1g/mol IUPAC Name: N-[(E,3R,4R,5R,9S,10S,11S)-10-hydroxy-11-[(1S,3S,4S,5S,7R,8S,9R,12E,14E,16S,17R,19R)-16-hydroxy-3,5,7,17-tetramethoxy-8,14-dimethyl-11-oxospiro[10,23-dioxabicyclo[17.3.1]tricos-12,14,20-triene-4,2'-oxirane]-9-yl]-4-methoxy-3,5,9-trimethyl-6-oxododec-1-enyl]-N-methylformamide	Moore, 1982
<i>Tolypothrix nodosa</i>	Tolyporphin J	MF: C ₂₄ H ₂₂ N ₄ O ₄ MW: 430.5g/mol IUPAC Name: 3,13-dihydroxy-3,7,13,18-tetramethyl-22,24-dihydroporphyrin-2,12-dione	Prinsep et al., 1992
<i>Fischerella ambigua</i>	Ambigol A	MF: C ₁₈ H ₈ Cl ₆ O ₃ MW: 485g/mol IUPAC Name: 3,5-dichloro-2(3,5-dichloro-2-hydroxyphenyl)-6-(2,4-dichlorophenoxy)phenol	Falch et al., 1995
<i>Nostoc muscorum</i>	Muscoride A	MF: C ₂₈ H ₄₀ N ₄ O ₅ MW: 512.6g/mol IUPAC Name: 3-methylbut-2-enyl 5-methyl-2-[5-methyl-2-[1-[3-methyl-2-(2-methylbut-3-en-2-ylamino)butanoyl]pyrrolidin-2-yl]-1,3-oxazol-4-yl]-1,3-oxazole-4-carboxylate	Nagatsu et al., 1995
<i>Fischerella ambigua</i>	Tjipanazole D	Compound CID: 10087661 MF: C ₁₈ H ₁₀ Cl ₂ N ₂ MW: 325.2g/mol IUPAC Name: 3,8-dichloro-11,12-dihydroindolo[2,3-a] carbazole	Falch et al., 1995
<i>Microcystis aeruginosa</i>	Kawaguchipeptin A	MF: C ₆₈ H ₉₂ N ₁₆ O ₁₈ MW: 1421.6g/mol IUPAC Name: 2-[(3S,9S,12S,15S,17S,25R,28S,31S,34S,40S,43R,46S,48S,56S)-28,31,40-tris(2-amino-2-oxoethyl)-9-[(1R)-1-hydroxyethyl]-12-(hydroxymethyl)-17,48-bis(3-methylbut-2-enyl)-43-(2-methylpropyl)-2,8,11,14,27,30,33,36,39,42,45-undeca-oxo-1,7,10,13,24,26,29,32,35,38,41,44,55-tridecazaoctacyclo[44.10.0.03,7.015,26.017,25.018,23.048,56.049,54]hexapentaconta-18,20,22,49,51,53-hexaen-34-yl]acetic acid	Ishida et al., 1997
<i>Nostoc spongiaeforme</i> var. <i>tenu</i>	Tenuecyclamide A	MF: C ₁₉ H ₂₀ N ₆ O ₄ S ₂ MW: 460.5g/mol IUPAC Name: (4S)-4,7,11,18-tetramethyl-6-oxa-13,20-dithia-3,10,17,22,23,24-hexazatetracyclo[17.2.1.15,8.112,15]tetracos-1(21),5(24),7,12(23),14,19(22)-hexaene-2,9,16-trione	Banker & Carmeli, 1998
<i>Nostoc commune</i>	1,8-dihydroxy-4-methyl anthraquinone	MF: C ₁₅ H ₁₀ O ₄ MW: 254.24g/mol IUPAC Name: 4,5-dihydroxy-1-methylanthracene-9,10-dione	Jaki et al., 2000
<i>Calothrix</i> sp.	Calothrixin A	MF: C ₁₉ H ₁₀ N ₂ O ₃ MW: 314.3g/mol IUPAC Name: 20-oxido-10-aza-20-azoniapentacyclo[11.8.0.03,11.04,9.014,19]henicosa-1(13),3(11),4,6,8,14,16,18,20-nonaene-2,12-dione	Doan et al., 2000

BGA Sps.	Antibacterial Compounds	Detail of Chemical compounds	References
<i>Nostoc commune</i>	Comnastin A	MF: C ₂₇ H ₄₀ O ₄ MW: 428.6g/mol IUPAC Name: 3-[[[(3R,3aR,5aS,6R,7R,9aS,9bR)-3-(hydroxymethyl)-3,3a,6,7,9a-pentamethyl-2,4,5,5a,7,8,9,9b-octahydro-1H-cyclopenta[a]naphthalen-6-yl]methyl]-4-hydroxybenzoic acid	Jaki et al., Jaki et al., 2000
<i>Nostoc</i> sp.	Nostocycline A	MF: C ₂₃ H ₃₄ O ₂ MW: 342.5g/mol IUPAC Name: 15-propylbicyclo[14.2.2]icosa-1(19),16(20),17-trien-2-yne-17,20-diol	Ploutno & Carmeli, 2000
<i>Nostoc spongiaeforme</i>	Nostocine A	MF: C ₅ H ₅ N ₅ O MW: 151.13g/mol IUPAC Name: 7-methyl-2H-pyrazolo[4,3-e][1,2,4]triazin-3-one	Hirata et al., 2003
<i>Oscillatoria redekei</i>	a-dimorphecolic acid	MF: C ₁₈ H ₃₂ O ₃ MW: 296.4g/mol IUPAC Name: (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid	Mundt et al., 2003
<i>Scytonema hofmanni</i> PCC 7110	Scyptolin A	MF: C ₄₅ H ₆₉ ClN ₈ O ₁₄ MW: 981.5g/mol IUPAC Name: (2S,3R)-2-[[[(2S)-2-(butanoylamino)propanoyl]amino]-N-[(2S,5S,8S,11R,12S,15S,18R,21R)-5-[(3-chloro-4-hydroxyphenyl)methyl]-21-hydroxy-2-[(1R)-1-hydroxyethyl]-4,11-dimethyl-15-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]-3-hydroxybutanamide	MacMillan & Molinski, 2005; Matern et al., 2001
<i>Lyngbya</i> sp.	Pahayokolide A	MF: C ₇₂ H ₁₀₅ N ₁₃ O ₂₀ MW: 1472.7g/mol IUPAC Name: [1-[(6R,10R,13S,19R,22S,25E,28S,31Z,34S,37S)-6-(3-amino-3-oxopropyl)-34-benzyl-25,31-di(ethylidene)-9-hydroxy-22-[(1R)-1-hydroxyethyl]-28-(hydroxymethyl)-2,5,8,12,18,21,24,27,30,33,36-undecaoxo-19-(2-phenylethyl)-1,4,7,11,17,20,23,26,29,32,35-undecazatricyclo[35.3.0.013,17]tetracontan-10-yl]-4,5-dihydroxy-7-methyloctan-2-yl] (2S)-2-[acetyl(methyl)amino]-4-methylpentanoate	Berry Berry et al., 2004
<i>Microcoleus lacustris</i>	Abietane	MF: C ₂₀ H ₃₆ MW: 276.5g/mol IUPAC Name: (2S,4aS,4bR,8aS,10aS)-4b,8,8-trimethyl-2-propan-2-yl-1,2,3,4,4a,5,6,7,8a,9,10,10a-dodecahydrophenanthrene	Thajuddin & Subramanian, 2005
<i>Fischerella</i> sp.	Hapalindole T	MF: C ₂₁ H ₂₃ ClN ₂ OS MW: 386.9g/mol IUPAC Name: (2S,6S,7R,8R,10R)-8-chloro-7-ethenyl-7,11,11-trimethyl-3-thia-5,17-diazapentacyclo[10.6.1.02,6.02,10.016,19]nonadeca-1(18),12(19),13,15-tetraen-4-one	Asthana et al., 2009
<i>Fischerella ambigua</i>	Ambigol B	MF: C ₁₈ H ₈ Cl ₆ O ₃ MW: 485g/mol IUPAC Name: 3,5-dichloro-2,6-bis(2,4-dichlorophenoxy)phenol	Raveh & Carmeli, 2007
<i>Nostoc</i> sp.	Carbamidocyclophane A	MF: C ₃₈ H ₅₄ Cl ₄ N ₂ O ₈ MW: 808.6g/mol IUPAC Name: [(2R,3S,13R,14S)-13-carbamoyloxy-8,19-bis(4,4-dichlorobutyl)-10,21,24,26-tetrahydroxy-3,14-dimethyl-2-tricyclo[18.2.2.29,12]hexacosa-1(22),9,11,20,23,25-hexaenyl] carbamate	Bui et al., 2007
<i>Nostoc</i> sp.	Nostocarboline Hydroiodide; Nostocarboline Iodide	MF: C ₁₂ H ₁₀ ClIN ₂ MW: 344.58g/mol IUPAC Name: 6-chloro-2-methyl-9H-pyrido[3,4-b]indol-2-ium;iodide	Becher et al., 2007
<i>Fischerella ambigua</i>	Ambiguine A isonitrile	MF: C ₂₆ H ₃₁ ClN ₂ MW: 407g/mol IUPAC Name: (2S,3R,4R,5R,7S)-5-chloro-4-ethenyl-3-isocyano-4,8,8-trimethyl-15-(2-methylbut-3-en-2-yl)-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),9(16),10,12-tetraene	Mo et al., 2009

BGA Sps.	Antibacterial Compounds	Detail of Chemical compounds	References
<i>Fischerella ambigua</i>	Ambiguine A isonitrile	MF: C ₂₆ H ₃₁ ClN ₂ MW: 407g/mol IUPAC Name: (2S,3R,4R,5R,7S)-5-chloro-4-ethenyl-3-isocyano-4,8,8-trimethyl-15-(2-methylbut-3-en-2-yl)-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),9(16),10,12-tetraene	Mo et al., 2009
<i>Leptolyngbya crosbyana</i>	Crossbyanol A	MF: C ₃₀ H ₁₅ Br ₇ O ₆ MW: 1030.8g/mol IUPAC Name: 3-bromo-4-[2-bromo-4-(3-bromo-4-hydroxyphenoxy)-6-(2,4-dibromophenoxy)phenoxy]-2-(2,4-dibromophenoxy)phenol	Choi et al., 2010
<i>Nostoc</i> sp. MGL001	9-Ethyliminomethyl-12-(morpholin-4-ylmethoxy) 5, 8, 13, 16-tetraaza-hexacene-2, 3 dicarboxylic acid (EMTAHDCa)		Niveshika et al., 2016

Scytophycins C

Tolytoxin

Tolyporphin J

Ambigol A

Muscoride A

Tjipanazole D

Kawaguchipectin A

Tenuocyclamide A

1,8-dihydroxy-4-methyl anthraquinone

Calothrixin A

Comnastin A

Nostocyclone A

Nostocine A

a-dimorphecolic acid

Scytolin A

Pahayokolide A

Figure 12 Chemical structures of the active ingredients isolated from various BGA and having antibacterial potential

2.1.2 Antimycobacterial potential of BGA

BGA extracts and compounds have been tested against various species of Mycobacteria. Rao et al. (2007) reported the antimycobacterial activity of different spp. of BGA viz., *Hapalosiphon* sp., *Anabaena* sp., *Lyngbya* sp., *Westeillopsis prolifica*, *Spirulina* sp., *Anabaena variabilis*, *Anabaena cylindrica*, *Oscillatoria* sp. and *Scytonema* sp. against *Mycobacterium tuberculosis* ATCC 27294, *M. tuberculosis* MDR, *M. avium*, *M. intracellulare*, and *M. aurum*. Other BGA species which exhibit antimycobacterial potential are *Tychonema* sp., *Fischerella ambigua* are *Lyngbya juscule* (Muller et al., 2006; Mo et al., 2009; Sturdy et al., 2010; Luesch et al., 2001). Antimycobacterial compounds produced by these BGA strains are summarized in Table 2.

2.1.3 Antifungal potential of BGA

Antifungal properties of BGA strains have been documented globally. Fungal and yeast strains such as *Candida friedrichi*, *Fusarium oxysporum*, *Aspergillus fumigatus*, *Alternaria alternate*, *A. niger*, *C. albicans*, *A. parasiticus*, *A. flavus*, *A. westerdijkia*, *A. ochraceus* ITAL 14, *A. carbonarius* ITAL 204, *A. steinii* IBT LKN 23096, *Penicillium verrucosum* BFE 500, *F. verticillioides* ITEM 10027, *F. proliferatum* MPVP 328 have been tested with BGA extracts and compounds (Marrez & Sultan, 2016; Vanlalveni et al., 2018; Saurav et al., 2019). Antifungal compounds reported from BGA strains have been listed in Table 3 and Figure 13.

2.1.4 Antioxidant potential of BGA

Blue-green algae produce large amounts of antioxidants to protect themselves from harmful stress conditions so that the cells can be protected from the effect of the reactive oxygen species (ROS) produced during stress. Hydrogen peroxide and oxygen free radicals are the two harmful reactive oxygen species formed in the cells during oxidative stress and can damage the cells (Vasudevan et al., 2020). Antioxidant properties of various extracts have been evaluated using different assay methods such as DPPH radical-scavenging Assay, ABTS⁺ (2, 2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid); Nitric oxide radical scavenging Assay; Total Antioxidant capacity determination kit, and β -carotene bleaching assay (Table 5). BGA produces several antioxidants that can scavenge these free radicals. These antioxidants have been explored as a novel source of dietary supplements because the cyanobacteria are rich in phenolics, vitamins, and carotenoids, the most common being carotenoids, which can be used for alleviating oxidative stress and limiting health problems (Nainangu et al., 2020; Gabr et al., 2020). ROS are also formed in animals and humans during oxidative stress and cause damage to the biomolecules such as lipids, proteins, and DNA. Oxidative stress is associated with several diseases such as cancer, neurodegeneration, retinopathy, aging, and other diseases. Algae produce several substances that have antioxidant effects, and these substances can be used as dietary supplements by humans (Guerreiro et al., 2020; Safari et al., 2020; Li et al., 2020). Antioxidant compounds recently purified from Blue-Green Algae are summarized in Table 4.

Table 2 Antimycobacterial compounds reported from BGA

BGA Spp.	Antimycobacterial Compounds	Chemical Structure	References
<i>Tychonema sp.</i>	<p>Brunsvicamide A MF: C₄₅H₆₄N₈O₈ MW: 845g/mol</p> <p>IUPAC Name: (2S)-2-[[[(3S,6S,9S,12S,15S)-3-benzyl-6-(1H-indol-3-ylmethyl)-7-methyl-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-propan-2-yl-1,4,7,10,13-pentazacyclononadec-15-yl]carbamoylamino]-3-methylpentanoic acid</p>		Muller et al., 2006
<i>Tychonema sp.</i>	<p>Brunsvicamide B MF: C₄₆H₆₆N₈O₈ MW: 859.1g/mol</p> <p>IUPAC Name: (2S)-2-[[[(3S,6S,9S,12S,15S)-3-benzyl-12-butan-2-yl-6-(1H-indol-3-ylmethyl)-7-methyl-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclononadec-15-yl]carbamoylamino]-3-methylpentanoic acid</p>		Muller et al., 2006
<i>Fischerella ambigua</i>	<p>Eucapsitrione MF: C₂₁H₁₀O₆ MW: 358.3g/mol</p> <p>IUPAC Name: 2,8,19-trihydroxypentacyclo[11.8.0.03,11.04,9.015,20]henicosa-1(13),2,4(9),5,7,11,15(20),16,18-nonaene-10,14,21-trione</p>		Sturdy et al., 2010
<i>Lyngbya majuscula</i>	<p>Pitipeptolide A MF: C₄₄H₆₅N₅O₉ MW: 808g/mol</p> <p>IUPAC Name: (3S,6S,9S,13S,19S,22S)-6-benzyl-3,19-bis[(2S)-butan-2-yl]-7,12,12-trimethyl-13-pent-4-ynyl-9-propan-2-yl-4,14-dioxo-1,7,10,17,20-pentazabicyclo[20.3.0]pentacosane-2,5,8,11,15,18,21-heptone</p>		Luesch et al., 2001
<i>Lyngbya majuscula</i>	<p>Pitipeptolides C MF: C₄₄H₆₉N₅O₉ MW: 812g/mol</p> <p>IUPAC Name: (3S,6S,9S,13S,19S,22S)-6-benzyl-3,19-bis[(2S)-butan-2-yl]-7,12,12-trimethyl-13-pentyl-9-propan-2-yl-4,14-dioxo-1,7,10,17,20-pentazabicyclo[20.3.0]pentacosane-2,5,8,11,15,18,21-heptone</p>		Mo et al., 2009

Table 3 Antifungal compounds reported from BGA

BGA Spp.	Antifungal Compounds	Detail of Chemical compounds	References
<i>Hyella caespitosa</i>	Carazostatin	MF: C ₂₀ H ₂₅ NO MW: 295.4g/mol IUPAC Name: 1-heptyl-2-methyl-9H-carbazol-3-ol	Cardellina et al., 1979a
<i>Scytonema hofmanni</i>	Cyanobacterin	MF: C ₂₃ H ₂₃ ClO ₆ MW: 430.9g/mol IUPAC Name: (5Z)-3-[(7-chloro-1,3-benzodioxol-5-yl)methyl]-4-hydroxy-5-[(4-methoxyphenyl)methylidene]-4-propan-2-yloxolan-2-one	Mason et al., 1982
<i>Tolypothrix tenuis</i>	Toyocamycin	MF: C ₁₂ H ₁₃ N ₅ O ₄ MW: 291.26g/mol IUPAC Name: 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile	Moore, 1982
<i>Tolypothrix tenuis</i>	Tubercidin	MF: C ₁₁ H ₁₄ N ₄ O ₄ MW: 266.25g/mol IUPAC Name: (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol	Moore, 1982; Banker & Carmeli, 1998
<i>Hapalosiphon fontinalis</i>	Anhydrohaloxindole A; Anhydrohapaloxindole A	MF: C ₂₁ H ₂₁ ClN ₂ O MW: 352.9g/mol IUPAC Name: (3R,4R,5R,7R)-5-chloro-4-ethenyl-3-isocyano-4,8,8-trimethyl-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1,9(16),10,12-tetraen-15-one	Moore et al., 1987
<i>Hapalosiphon fontinalis</i>	Fontonamide	MF: C ₂₀ H ₂₂ ClNO ₂ MW: 343.8g/mol IUPAC Name: N-[(6R,7R,10aR)-6-chloro-7-ethenyl-7,10,10-trimethyl-9-oxo-6,10a-dihydro-5H-anthracen-1-yl]formamide	Moore et al., 1987
<i>Nostoc</i> sp.	Nostocyclamide	MF: C ₂₀ H ₂₂ N ₆ O ₄ S ₂ MW: 474.6g/mol IUPAC Name: (4S,18R)-4,7-dimethyl-18-propan-2-yl-6-oxa-13,20-dithia-3,10,17,22,23,24-hexazatetracyclo[17.2.1.15,8.112,15]tetracosal-1(21),5(24),7,12(23),14,19(22)-hexaene-2,9,16-trione	Moore et al., 1988
<i>Hormothamnion enteromorphoides</i>	Hormothamnin A	MF: C ₆₀ H ₉₇ N ₁₁ O ₁₄ MW: 1196.5g/mol IUPAC Name: (3Z)-28-benzyl-19,22-di(butan-2-yl)-3-ethylidene-36-hydroxy-6,31-bis(2-hydroxyethyl)-16,25-bis(2-methylpropyl)-10-pentyl-1,4,7,11,14,17,20,23,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-2,5,8,12,15,18,21,24,27,30,33-undecone	Gerwick et al., 1989
<i>Calothrix fusca</i>	Calophycin	MF: C ₁₉ H ₁₈ N ₂ O ₃ MW: 322.4g/mol IUPAC Name: (3R)-2-[(4-hydroxyphenyl)methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylic acid	Moon et al., 1992
<i>Dichothrix baueriana</i>	Bauerine B	MF: C ₁₂ H ₈ Cl ₂ N ₂ MW: 251.11g/mol IUPAC Name: 7,8-dichloro-9-methylpyrido[3,4-b]indole	Larsen et al., 1994
<i>Nostoc</i> sp. ATCC 53789)	Cryptophycin 1	MF: C ₃₅ H ₄₃ ClN ₂ O ₈ MW: 655.2g/mol IUPAC Name: (3S,6R,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxo-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone	Trimurtulu et al., 1994
<i>Hapalosiphon welwitschii</i> , <i>Westiella intricate</i>	Welwitindolinone A isonitrile	MF: C ₂₁ H ₂₁ ClN ₂ O MW: 352.9g/mol IUPAC Name: (3S,3'S,4'R,6'R)-4'-chloro-3'-ethenyl-2'-isocyano-3',7',7'-trimethylspiro[1H-indole-3,8'-bicyclo[4.2.0]oct-1-ene]-2-one	Stratmann et al., 1994

BGA Spp.	Antifungal Compounds	Detail of Chemical compounds	References
<i>Nostoc commune</i>	Nostofungicidine	MF: C ₄₈ H ₇₆ N ₁₀ O ₁₈ MW: 1081.2g/mol IUPAC Name: 2-[16-(2-amino-1-hydroxy-2-oxoethyl)-27-hydroxy-19-[hydroxy-(4-hydroxyphenyl)methyl]-3,22-bis(hydroxymethyl)-10-(3-hydroxypentadecyl)-2,5,8,12,15,18,21,24-octaoxo-1,4,7,11,14,17,20,23-octazabicyclo[23.3.0]octacosan-13-yl]-2-hydroxyacetamide	Kajiyama et al., 1998
<i>Fischerella muscicola</i>	Fischerellin B	MF: C ₂₀ H ₂₉ NO MW: 299.4g/mol IUPAC Name: (3R,5S)-3-methyl-5-[(E)-pentadec-5-en-7,9-diynyl]pyrrolidin-2-one	Srivastava et al., 1999
<i>Lyngbya majuscula</i>	Tanikolide	MF: C ₁₇ H ₃₂ O ₃ MW: 284.4g/mol IUPAC Name: (6R)-6-(hydroxymethyl)-6-undecyloxan-2-one	Singh et al., 1999
<i>Scytonema pseudo hofmanni</i>	Scytophycin A	MF: C ₄₅ H ₇₅ NO ₁₂ MW: 822.1g/mol IUPAC Name: N-[(E,3R,4R,5S,9S,10S,11S)-6,10-dihydroxy-11-[(1S,3S,4S,5S,7R,8S,9R,12E,14E,17S,19R)-17-hydroxy-3,5,7-trimethoxy-8,14-dimethyl-11-oxospiro[10,23-dioxabicyclo[17.3.1]tricosan-12,14,20-triene-4,2'-oxirane]-9-yl]-4-methoxy-3,5,9-trimethyldodec-1-enyl]-N-methylformamide	Matern et al., 2001
<i>Tolypothrix byssodea</i>	Tolybyssidin A	MF: C ₇₁ H ₁₁₆ N ₁₆ O ₁₇ MW: 1465.8g/mol IUPAC Name: [(1R)-1-[(3S,6S,9S,12S,15S,18Z,21S,24S,27S,30S,33R,36S,39S)-21-benzyl-24,27-bis[(2S)-butan-2-yl]-36-[3-(diaminomethylideneamino)propyl]-18-ethylidene-9,30-bis[(1R)-1-hydroxyethyl]-33-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxo-3,6,15-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31,34,37-tridecazabicyclo[37.3.0]dotetracontan-12-yl]ethyl] acetate	Jaki et al., 2001
<i>Tolypothrix byssodea</i>	Tolybyssidin B	MF: C ₇₂ H ₁₁₄ N ₁₆ O ₁₆ S MW: 1491.8g/mol IUPAC Name: 2-[3-[(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38E)-32-benzyl-17-[(2S)-butan-2-yl]-38-ethylidene-14,20-bis[(1R)-1-hydroxyethyl]-5-[(4-hydroxyphenyl)methyl]-8-(2-methylsulfanylethyl)-3,6,9,12,15,18,21,24,27,30,33,36,39-tridecaoxo-11,23,26,29,35-penta(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31,34,37-tridecazacyclononatriacont-2-yl]propyl]guanidine	Jaki et al., 2001
<i>Lyngbya confervoides</i>	Lobocyclamine B	MF: C ₆₅ H ₁₁₅ N ₁₃ O ₂₀ MW: 1398.7g/mol IUPAC Name: 3-[(3S,6R,9S,12R,15R,18S,21R,24S,28R,31S,34R,37S,39R)-9-[(2S)-butan-2-yl]-6-[(1R)-1,2-dihydroxyethyl]-28-heptyl-39-hydroxy-3,31-bis[(1R)-1-hydroxyethyl]-15,21-bis[(1S)-1-hydroxy-2-methylpropyl]-10,18-dimethyl-34-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,30,33,36-dodecaoxo-24-propan-2-yl-1,4,7,10,13,16,19,22,25,29,32,35-dodecazabicyclo[35.3.0]tetracontan-12-yl]propanamide	MacMillan et al., 2002
<i>Nostoc commune</i>	Nostodione A	MF: C ₁₈ H ₁₁ NO ₃ MW: 289.3g/mol IUPAC Name: (3E)-3-[(4-hydroxyphenyl)methylidene]-4H-cyclopenta[b]indole-1,2-dione	Bhadury & Wright, 2004
<i>Hassallia</i> sp.	Hassallidin A	MF: C ₆₂ H ₉₉ N ₁₁ O ₂₄ MW: 1382.5g/mol IUPAC Name: N-[(2S,3R)-1-[(3S,6S,12S,15Z,18S,21S,24S,25R)-3,12-bis(3-amino-3-oxopropyl)-15-ethylidene-21-[(1R)-1-hydroxyethyl]-18-[(4-hydroxyphenyl)methyl]-7,25-dimethyl-2,5,8,11,14,17,20,23-octaoxo-6-[(1R)-1-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-1-oxa-4,7,10,13,16,19,22-heptazacyclopentacos-24-yl]amino]-3-hydroxy-1-oxobutan-2-yl]-2,3-dihydroxytetradecanamide	Neuhof et al., 2005

BGA Spp.	Antifungal Compounds	Detail of Chemical compounds	References
<i>Fischerella ambigua</i>	2,4-dichlorobenzoic acid	MF: C ₇ H ₄ Cl ₂ O ₂ MW: 191.01g/mol IUPAC Name: 2,4-dichlorobenzoic acid	Wright et al., 2005
<i>Geitlerinema</i> sp.	Swinholide A	MF: C ₇₈ H ₁₃₂ O ₂₀ MW: 1389.9g/mol IUPAC Name: (1R,3S,5E,7E,11S,12S,13R,15S,16S,17S,19S,23R,25R,27Z,29E,33S,34S,35R,37S,38S,39S,41S)-3,13,15,25,35,37-hexahydroxy-11-[(2S,3S,4R)-3-hydroxy-6-[(2S,4R,6S)-4-methoxy-6-methyloxan-2-yl]-4-methylhexan-2-yl]-33-[(2S,3S,4S)-3-hydroxy-6-[(2S,4R,6S)-4-methoxy-6-methyloxan-2-yl]-4-methylhexan-2-yl]-17,39-dimethoxy-6,12,16,28,34,38-hexamethyl-10,32,45,46-tetraoxatricyclo[39.3.1.119,23]hexatetraconta-5,7,21,27,29,43-hexaene-9,31-dione	Andrianasolo et al., 2005
<i>Fischerella ambigua</i>	Tjipanazole B	MF: C ₂₃ H ₁₈ Cl ₂ N ₂ O ₄ MW: 457.3g/mol IUPAC Name: (2R,3R,4S,5R)-2-(3,8-dichloro-1H-indolo[2,3-a]carbazol-12-yl)oxane-3,4,5-triol	Wright et al., 2005
<i>Nadularia harveyana</i>	Norharmane	MF: C ₁₁ H ₈ N ₂ MW: 168.19g/mol IUPAC Name: 9H-pyrido[3,4-b]indole	Volk & Furkert, 2006
<i>Synechocystis</i> sp.	AK-3	MF: C ₉ H ₁₆ N ₄ OS MW: 228.32g/mol IUPAC Name: 2-(dimethylamino)-N-(5-propyl-1,3,4-thiadiazol-2-yl)acetamide	Yoon et al., 2006
<i>Lyngbya majuscula</i>	Hectochlorin	MF: C ₂₇ H ₃₄ Cl ₂ N ₂ O ₉ S ₂ MW: 665.6g/mol IUPAC Name: [(5S,12S,13S,16S)-12-(4,4-dichloropentyl)-16-(2-hydroxypropan-2-yl)-4,4,13-trimethyl-2,10,14-trioxo-3,11,15-trioxa-7,18-dithia-20,21-diazatricyclo[15.2.1.16,9]henicosa-1(19),6(21),8,17(20)-tetraen-5-yl] acetate	Gademann & Portmann, 2008
<i>Calothrix elenkini</i>	Benzoic Acid	MF: C ₇ H ₆ O ₂ MW: 122.12g/mol IUPAC Name: benzoic acid	Natarajan et al., 2012

Carazostatin

Cyanobacterin

Toyocamycin

Tubercidin

Anhydrohaloxindole A;
Anhydrohapaloxindole A

Fontonamide

Nostocyclamide

Hormothamnin A

Figure 13 Chemical structures of the active ingredients isolated from various BGA and having antifungal properties

Table 4 Antioxidants compounds recently purified from Blue-Green Algae

Antioxidants compounds	Source	References
Pyrogallol, E-Vanillic, Hespirdin	<i>Spirulina platensis</i>	Gabr et al., 2020
Benzenacetanamide and Norvaline, n-propargyloxycarbonyl	<i>Microcystis aeruginosa</i>	Vasudevan et al., 2020
BHA, Beta tocopherol, Phytosterols	<i>Spirulina maxima</i>	Gamal et al., 2020
Caffeic acid, syringic acid, ferulic acid, p-coumaric acid, chlorogenic acid, kaempferol, quercetin and apigenin γ -linolenic acid, α -linolenic acid	<i>Spirulina platensis</i>	Bellahcen et al., 2020
Benzoic acid, 4-(1-azepinyl)azo-, ethyl ester (b) 1,6-methanonaphthalen-1(2H)-ol, octahydro-4,8a,9,9-tetramethyl, (c) Dibutyl phthalate, (d) 1,2-benzene dicarboxylic acid, (e) Hexadecanoic acid, 2-pentadecyl-1,3-dioxan-5-yl ester	<i>Oscillatoria</i> sp. SSCM01	Nainangu et al., 2020

Table 5 Types of BGA Extracts, Assay methods and their antioxidant potential

Blue-Green Algae	Type of Extract	Assay methods	Maximum Activity	References
<i>Spirulina platensis</i>	Ethanollic and aqueous extract	DPPH radical-scavenging Assay	96.33%	Gabr et al., 2020
<i>Microcystis aeruginosa</i>	Methanol Extract	Scavenging ability on 1, 1-diphenyl-2-picrylhydrazyl radicals (DPPH) Hydroxyl radical scavenging assay	54% 49%	Vasudevan et al., 2020
<i>Spirulina maxima</i>	-	DPPH radical-scavenging Assay	25.73 %	Gamal et al., 2020
<i>Spirulina platensis</i>	Ethanollic, aqueous, and lipidic extracts	Diphenyl-1-picrylhydrazyl (DPPH) Azino-bis (ethylbenzthiazoline-6-sulfonic acid) (ABTS)	(IC ₅₀ =449 μ g/mL $\pm$ 83) (IC ₅₀ =740 μ g/mL $\pm$ 12)	Bellahcen et al., 2020
<i>Oscillatoria</i> sp. SSCM01	MeOH: CHCl ₃ fraction	DPPH radical scavenging assay	48%	Nainangu et al., 2020
<i>Spirulina platensis</i>	crude extracts	DPPH radical-scavenging activity	45.75%	Safari et al., 2020
<i>Oscillatoria acuminata</i>	Methanolic extract	DPPH (2, 2- diphenyl-1-picrylhydrazyl) ABTS ⁺ (2, 2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid))	6.58 % 34.60 %	Gheda & Ismail (2020).
<i>Dolichospermum flos-aquae</i> HSSASE2		DPPH radical scavenging assay Nitric oxide radical scavenging assay Anti-lipid peroxidation assay	(467.7 μ g/ml) (IC ₅₀ = 28.7 $\pm$ 0.1 μ g/ml) (IC ₅₀ 11.9 $\pm$ 0.2 μ g/ml)	Senousy et al., 2020
<i>Anabaena</i> sp., <i>Stigonema</i> sp. and <i>Oscillatoria</i> sp.	Methanol Extract	Total Antioxidant capacity determination kit	0.346 (mM/L); 0.36 (mM/L) and 0.37 (mM/L)	Seddek et al., 2019
<i>Aphanizomenon gracile</i> (LMCYA 009), <i>Aphanizomenon flos-aquae</i> (LMCYA 088), <i>Nostoc</i> (LMCYA 291), <i>Plankto thrixmougeotii</i> (LEGE 06224)	Methanolic and ethanolic	DPPH scavenging method, β -carotene bleaching assay	10.7% 828.94 AAC	Guerreiro et al., 2019

2.1.5 Anti-cancer potential of BGA

BGA extracts and compounds are known to exhibit anticancer properties (Shishido et al., 2020; Gara-Ali et al., 2021). Research by Jaspers & Lawton (1998) has focused on various biologically active compounds from BGA. The *curian A*, a novel lipid compound isolated from *Lyngbya majuscula*, is a potent inhibitor of microtubule assembly with very low IC_{50} values against L1210 leukemia cells and CD-46 Burkitt lymphoma cells, at par with those for colchicines. Cryptophycin 1 and 8, another anticancer compound was first isolated from *Nostoc* sp. by researchers at Merck. The oral supplement of *Spirulina fusiformis* is known for regression of subjects with homogenous leukolakia (Mathew et al., 1995). The extracts of *Spirulina* and *Dunaliella* inhibited the chemically induced carcinogenesis in model hamster buccal pouches (Schwartz et al., 1988). Studies have also shown that sulphated polysaccharide, calcium spirulans appears to inhibit tumor invasion of melanoma cells and basement membrane

(Mishima et al., 1998). *Aphanizomenon flosaquae* extract containing a high concentration of phycocyanin inhibited the *in vitro* growth of tumour cells, indicating the sensitivity of cell lines to the phycocyanin. A filamentous cyanobacterium *Phormidium tenue* contains several diacylglycerols that inhibit chemically induce tumors on mice (Tokuda et al., 1996). Similarly, cryptophycin 1 isolated from *Nostoc* sp. (ATCC 53789) is the most potent suppressor of microtubule dynamics *i.e.* it blocks all cell cycles in G2/M phase. Curacin A is isolated from *Lyngbya majuscula*. This compound is found to be a potent inhibitor of microtubule assembly. There is a need for immediate attention for more novel anticancer drugs so that carcinogenic cells are capable of resisting some drugs, like vinca alkaloids and taxanes. These drugs failed to treat cancer in a chemotherapeutic way. Cancer is known to be the major cause of mortality worldwide. Recently some new types of cancer e.g. glioblastoma are increased rapidly. Anticancer compounds reported from BGA are summarized in Table 6 Figure 14.

Table 6 Anticancer compounds reported from BGA

BGA Spp.	Anticancer Compounds	Chemical Structure	References
<i>Calothrix</i> sp.	Calothrixin A	MF: C ₁₉ H ₁₀ N ₂ O ₃ MW: 314.3g/mol IUPAC Name: 20-oxido-10-aza-20-azoniapentacyclo[11.8.0.0.3,11.0.4,9,0.14,19]henicosa-1(13),3(11),4,6,8,14,16,18,20-nonaene-2,12-dione	Cardellina et al., 1979b
<i>Nostoc</i> sp.	Boromycin	MF: C ₄₅ H ₇₄ BNO ₁₅ MW: 879.9g/mol IUPAC Name: [(2R)-1-[(1R)-1-[(1R,5S,7E,11S,13S,16R,17R,24S,25R,27R,31R,33S,36R)-11,31-dihydroxy-12,12,16,25,32,32,36-heptamethyl-3,22-dioxo-4,18,20,23,26,37,38,40,41-nona-oxa-19-boranuideheptacyclo[17.17.1.1.1,33.12,19.113,17.124,27.017,21]hentetracont-7-en-5-yl]ethoxy]-3-methyl-1-oxobutan-2-yl]azanum	Banker & Carmeli, 1998; Gupta, 2012
<i>Scytonema varium</i>	Scytovirin	MF: C ₆₆ H ₉₁ N ₁₉ O ₂₄ S MW: 1566.6g/mol IUPAC Name: (4S)-4-[[[(2S)-4-amino-2-[[[(2S)-2-[[[(2R)-2-[[[(2S,3R)-2-[[[(2S)-1-[2-[[[(2S)-2-[(2-aminoacetyl)amino]-3-hydroxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-[[[(2S)-1-[[[(2S)-4-amino-1-[[[(2S)-4-amino-1-[(2S)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	Shi et al., 1999
<i>Symploca</i> genus	Largazole	MF: C ₂₉ H ₄₂ N ₄ O ₅ S ₃ MW: 622.9g/mol IUPAC Name: S-[(E)-4-[(5R,8S,11S)-5-methyl-6,9,13-trioxo-8-propan-2-yl-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-enyl] octanethioate	Luesch et al., 2001
<i>Nostoc</i> sp.	Apratoxin A	MF: C ₄₅ H ₆₉ N ₅ O ₈ S MW: 840.1g/mol IUPAC Name: (2S,3S,5S,7S,10S,16S,19S,22S,25E,27S)-16-[(2S)-butan-2-yl]-7-tert-butyl-3-hydroxy-22-[(4-methoxyphenyl)methyl]-2,5,17,19,20,25-hexamethyl-8-oxa-29-thia-14,17,20,23,30-pentazatricyclo[25.2.1.0.10,14]triaconta-1(30),25-diene-9,15,18,21,24-pentone	Grinberg et al., 2002

BGA Spp.	Anticancer Compounds	Chemical Structure	References
<i>Dolabella auricularia</i>	Dolastatin 15	MF: C ₄₅ H ₆₈ N ₆ O ₉ MW: 837.1g/mol IUPAC Name: [(2S)-1-[(2S)-2-benzyl-3-methoxy-5-oxo-2H-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2S)-1-[(2S)-1-[(2S)-2-[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylate	Stevenson et al., 2002
Cyanobacteria	Astaxanthin	-	Chen et al., 2003
<i>Nostoc</i> sp.	Cryptophycin	MF: C ₃₅ H ₄₃ ClN ₂ O ₈ MW: 655.2g/mol IUPAC Name: (3S,6R,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxo-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone	Back & Liang 2005; Medina et al., 2008
<i>L. majusculata</i>	Curacin A	MF: C ₂₃ H ₃₅ NOS MW: 373.6g/mol IUPAC Name: (4R)-4-[(1Z,5E,7E,11R)-11-methoxy-8-methyltetradeca-1,5,7,13-tetraenyl]-2-[(1R,2S)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole Isomeric SMILES: C[C@H]1C[C@H]1C2=N[C@@H](CS2)/C=C/CC/C=C/C=C(C)/CC[C@H](CC=C)OC	Xiong et al., 2006
<i>Lyngbya</i> sp.	Dragonamide C	MF: C ₃₃ H ₅₇ N ₅ O ₆ MW: 619.8g/mol IUPAC Name: (E)-N-[(2S)-1-[[[(2S)-1-[[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methoxy-N-methyloct-2-en-7-ynamide	Gunasekera et al., 2008
<i>Lyngbya</i> sp.	Dragonamide D	MF: C ₃₂ H ₅₅ N ₅ O ₆ MW: 605.8g/mol IUPAC Name: N-[(2S)-1-[[[(2S)-1-[[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-N-methyl-3-oxooct-7-ynamide	Gunasekera et al., 2008

Calothrixin A

Boromycin

Scytovirin

Largazole

Apratoxin A

Dolastatin 15

Figure 14 Chemical structures of the active ingredients isolated from various BGA and having anticancerous properties

2.1.6 Antiviral Potential including SARS-CoV-2

The globe is so much affected by the dreadful diseases caused by infection of viruses such as HIV-acquired immune deficiency syndrome. There is also another viral deadly disease that is dengue which may have many consequences. Despite two former major outbreaks of coronavirus infections i.e. the SARS and MERS, the world is still underprepared to effectively manage the current COVID-19 pandemic outbreak. The researchers were in search of a novel and potent drug which will be able to resist those deadly and dreadful viral infections throughout the world. Scientists have now invented novel, potent, and safe anti-viral agents that are very useful in this urgent situation. Recently there is a new scientific treatment or therapy which is named highly active antiretroviral therapy in short HAART. This is triple therapy which is very fruitful and capable in the treatment of HIV infections which is very helpful and makes control and resistance power in carcinogenic treatment. This therapy can create strong viral resistance. But this therapy cannot stop the viral agent which is causing such kinds of issues. BGA species are also known to produce substances that have been proved to be anti-HIV, therefore can be exploited in therapy against AIDS (Schaeffer & Krylov, 2000; Carpine & Sieber, 2021)

Gustafson et al. (1989) used a tetrazolium-based micro-culture to screen extracts of cultured marine cyanobacteria, *Lyngbyalager heimii*, and *Phormedium tenue*, for the inhibition of HIV-1. This led to the discovery of sulfonic acid containing glycolipids as a new class of HIV-1- inhibitory compounds. Other cyanobacteria, *Phormedium cebemse*, *Oscillatoria raciborskii*, *Scytonem aburmanicum*, *Calothrix elenkinii*, and *Anabaena variabilis*, gave extracts that inhibited HIV-1 and gave positive tests for the presence of sulfolipids.

Compounds and extracts with anti-HIV activity are also active against other retroviruses such as Herpes simplex virus (HSV) and respiratory syncytial virus, but the amount of antiviral activity varies with the compound and the virus. Most of the research has focused on sulphated homopolysaccharides and heteropolysaccharides, sulfoglycolipids, carrageenans, fucoidan, sesquiterpene hydroquinones, and other classes of compounds with an anti-HIV activity that has been isolated from algae have received less attention. Hayashi et al. (1996) isolated calcium spirulan, a sulfated polysaccharide obtained from a marine blue-green alga, *Spirulina platensis* which inhibited the Herpes simplex virus. Subsequently, Ayehunie et al. (1998) determined that an aqueous extract of *S. platensis*, at a concentration that was non-toxic to human cells, inhibited syncytium formation and HIV-1

replication in human T-cell lines, peripheral blood mononuclear cells, and Langerhans cells. The antiviral effects of polysaccharides from marine algae towards mumps virus and influenza B virus were reported by Gerber et al. (1958). Subsequently, polysaccharides fractions from extracts of red algae were found to inhibit the herpes simplex virus (HSV). Similarly, Boyd et al. (1997) isolated Cyanovirin-N from an aqueous cellular extract of cyanobacterium *Nostoc ellipsosporum* which has been proved to be antiviral. Lau et al., (1993) reported that the lipophilic and hydrophilic extracts of over 900 strains of cultured blue-green algae *in vitro* for their ability to inhibit the reverse transcriptases of avian myeloblastosis virus (Table 7)

Various compounds have been isolated from a variety of blue-green algae BGA-derived polysaccharides that have been reported for the inhibition of SARS-CoV-2 (Sami et al., 2021). Few

organizations are actively involved in developing algae-based edible vaccines for SARS-CoV-2 (Jafari et al., 2021) (Table 8)

2.1.7 Antidiabetic Potential of BGA

Blue-green algae are known to exhibit potential antidiabetic properties. In a study conducted by Priatni et al. (2016) methanol extract of marine cyanobacterial strains such as *Oscillatoria limnetica*, *Coelastrella* sp., *Oscillatoria* sp., *Chroococcus* sp., *Leptolyngbya* sp., *Pseudanabaena* sp., *Lyngbya* sp., *Aphanothece* sp., *Phormidium* sp., and *Synechococcus* sp. have potential antidiabetic potential. The metabolites of *Pseudanabaena* sp. showed the highest α -glucosidase inhibition. In another study, Egyptian Scientists evaluated extracts of *Fischerella* sp. BS1-EG for antidiabetic

Table 7 Antiviral Compounds reported from BGA

BGA Sp.	Anti Viral Compound	Chemical Structure	References
<i>Nostoc ellipsosporum</i>	Cyanovirin-N		Boyd et al., 1997;; Bewley, 2001
<i>Microcystis aeruginosa</i>	Microvirin		Kehr et al., 2006
<i>Scytonema varium</i>	Scytovirin MF: C ₆₆ H ₉₁ N ₁₉ O ₂₄ S MW: 1566.6g/mol IUPAC Name: (4S)-4-[[[(2S)-4-amino-2-[[[(2S)-2-[[[(2R)-2-[[[(2S)-2-[[[(2S,3R)-2-[[[(2S)-1-[2-[[[(2S)-2-[(2-aminoacetyl)amino]-3-hydroxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-[[[(2S)-1-[[[(2S)-4-amino-1-[[[(2S)-4-amino-1-(2S)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid		Bokesch et al., 2003
<i>M. viridis</i> NIES-02	Microcystis Viridis Lectin	NA	Yamaguchi et al., 1999
<i>Arthrospira platensis</i>	Calcium Spirulan	NA	Hayashi et al., 1996

Table 8 Anti-HIV activity of compounds from BGA

BGA strains	Compounds	References
<i>Anabaena variabilis</i> , <i>Calothrix elenkini</i> , <i>Lyngbya lagerheimii</i> , <i>Phormidium tenue</i> , <i>Phormidium cebennense</i> , <i>Oscillatoria raciborskii</i> , <i>Scytonema burmanicum</i>	Extracts containing sulfolipids (sulfoquinovosyl diacylglycerols)	Gustafson et al., 1989
<i>Spirulina platensis</i>	activity in polysaccharide fraction	Ayehunie et al., 1998
<i>Spirulina platensis</i> (Marine)	Calcium spirulan, Ca-SP (sulfated polysaccharide fraction) Dextran sulfate	Hayashi et al., 1996
<i>Nostoc ellipsosporum</i>	Cyanovirin- N (11-k Da antiviral protein)	Gustafson et al., 1996
<i>Nostoc ellipsosporum</i>	Cyanovirin- N (11-k Da antiviral protein)	Boyd et al., 1996
900 strains	Lipophilic and Hydrophilic extracts	Lau et al., 1993
<i>Scytonema spp.</i>	Sulfoglycolipids	Reshef et al., 1997
<i>Oscillatoria spp.</i>	Acylated diglycolipids	Reshef et al., 1997
<i>Oscillatoria raoi</i> (TAU IL-76-12), <i>Syctonema spp.</i> (TAU SL-30-1-4), <i>Oscillatoria trichoides</i> (TAU IL 104-3-2), <i>Phormidium tenue</i> (TAU IL-144-1), <i>Oscillatoria limnetica</i> , <i>Lammermann</i> (TAU NG-4-1-2)	Sulfolipids, Sulfoglycolipids, hydrolysis products, synthetic derivative	Loya et al., 1998

Figure 15 Chemical structure of Anti-inflammatory compounds Tolypodiol isolated from *Tolypothrix nodosa*

potential and have reported certain bioactive compounds responsible for the activity (Ahmed et al., 2018). In a recent study, Sridhar et al. (2021) have evaluated phycocyanin of *S. platensis* for its antidiabetic potential by assessing α -amylase and β -glucosidase enzyme inhibition using spectroscopy techniques. In this *in vitro* test, significant Antidiabetic activity (88%) was observed at a concentration of 250 μ g/ml. In some studies, lesser antidiabetic properties have been reported, like Ghosh et al. (2016) evaluated *in vitro* antidiabetic properties of molecules from *Lyngbya*, *Microcoleus*, and *Synechocystis* sp. by α -amylase inhibition method and stated the lesser enzyme inhibition effect. Similarly, Xu et al. (2012) described the lowest α -amylase enzyme inhibition activity of *Phlorotannins* pigments extracted from *Eckloniakurome*. However, Hwang et al. (2014) reported 65 - 80% inhibitory activity at the concentration of 250 μ g/ml while this was reported 51 - 67% at the dose of 200 μ g/ml dose of *S. platensis* phycocyanin. Lesser enzyme inhibition even in higher concentrations was reported in a study conducted by Priatni et al. (2016).

2.1.8 Anti-inflammatory Activity of BGA

Blue-Green Algae contain a significant amount of carotenoids *i.e.* β -carotene, lycopene, lutein having antioxidant properties. By the quenching action on the reactive oxygen species, these carotenoids also have anti-inflammatory activity. This anti-inflammatory activity might be due to the presence of phycocyanin, a photo harvesting pigment. Further, the anti-inflammatory effect seemed to be the result of leucotriene formation inhibition by phycocyanin, an inflammatory metabolite of arachidonic acid (Romy et al., 1999). *Apbanizomenon flosaquae* decrease the level of arachidonic acid. Further, *A. flosaquae* and *Spirulina* contain significant amount of omega-3-alpha linolenic acid which inhibits the formation of inflammatory prostaglandins and arachidonate metabolites (Figure 15).

3 Conclusion and Future possibilities

BGA are groups of extraordinary, diverse, gram-negative, oxygenic, photosynthetic prokaryotic microscopic organisms.

Blue-green algae are found all over the world, showing remarkable ecological diversity of habitats such as freshwater, terrestrial, marine, hot spring, etc. These BGA are also widely distributed in the polar region such as the Arctic, Antarctic, Southern Ocean, and the Himalayas. Several studies have been conducted for the isolation and identification of Blue-Green algae from the water, soil, sediments, algal mats, etc. using advanced morphological, physiological, and molecular characterization techniques. Various selective media are known for their Cultivation. It has been now proven that BGA offers a great opportunity as these are considered to be one of the potential organisms useful to mankind in many ways. They exhibit diverse biological activities (Antibacterial, Antifungal, Anticancer, Antiviral Antidiabetic, and many more). Various bioactive molecules have been reported by researchers globally. In pharmaceutical companies especially in the new drug discovery research division, for the last many year's research is going on at various levels starting from extraction, purification, and identification of new compounds or drugs from various species of BGA. The major challenge in front of the current world is to fight effectively against the new emerging diseases and microbes specifically WHO priorities list of multiple antibiotic-resistant bacteria, microbial infections including SARS-CoV-2 virus and Cancer, etc., and to discover new pharmaceutical compounds for mankind and society. At the same time, there is an urgent need to think from basic to applied research to commercialize several value-added products. The use of nanomaterials to enhance biological activity could be one of the ways. Inventions of these drugs using nanotechnology can lead to the development of novel pharmaceuticals. Based on the cultures of cells, activities of enzymes, and receptors binding with ligands, various new technologies are invented to develop novel things of miniaturized screens. As a result, there is a conformational analysis, i.e., an analysis of the spatial arrangement of the component atom within a molecule that can be rotated about one or more single bonds. The known ligands result in the development of new compounds of structure-based drug design. Hence, the pharmaceutical potential of blue-green algae deserves more scientific attention and interdisciplinary research, and BGA strains from still unexplored and extreme habitats such as the Antarctic, Arctic, and the Himalayas can serve as good candidates in this regard.

Authors' contributions

All authors contributed significantly to the conception and design of the study, the interpretation of data, and the drafting and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors acknowledge the support of Dr. Ashok K. Chauhan, Founder President, Amity Universe, for his constant support and

encouragement. The authors also thank Dr. Atul Chauhan, Chancellor, Amity University, Uttar Pradesh, for providing all the required facilities.

Conflict of Interest

The authors hereby declare no conflict of interest.

Funding support

The authors declare that they have no funding support for this study

References

- Ahmed BE, Badawi MH, Mostafa SS, Higazy AM (2018) Human anticancer and antidiabetic activities of the cyanobacterium *Fischerella* sp. BS1-EG isolated from River Nile. Egypt. International Journal Current Microbiology and Applied Science 7(1): 3473-3485.
- Allen MB, Arnon DI (1955) Studies on nitrogen fixing blue green algae. I. growth and nitrogen fixation in *Anabaena cylindrica*. Plant Physiology 30: 366-372.
- Al-Saman MA, Doleib NM, Ibrahim MR, Nasr MY, Tayel AA, Hamouda RA (2020) In vitro and in vivo hypolipidemic properties of the aqueous extract of *Spirulina platensis*, cultivated in colored flasks under artificial illumination. PeerJ 8: e10366.
- Andrianasolo EH, Gross H, Goeger D, Musafija-Girt M, McPhail K, Leal RM, Mooberry SL, Gerwick WH (2005) Isolation of swinholide A and related glycosylated derivatives from two field collections of marine cyanobacteria. Organic letters 7(7):1375-8.
- Asthana RK, Tripathi MK, Srivastava A, Singh AP, Singh SP, Nath G, Srivastava R, Srivastava BS (2009) Isolation and identification of a new antibacterial entity from the Antarctic cyanobacterium Nostoc CCC 537. Journal of Applied Phycology 21(1):81-8.
- Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT (2021) Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery 20(3):200-216. doi: 10.1038/s41573-020-00114-z.
- Ayehunie S, Belay A, Baba TW, Ruprecht RM (1998) Inhibition of HIV-1 replication by an aqueous extract of *Spirulina platensis* (*Arthrospira platensis*). Journal of Acquired Immune Deficiency Syndrome 18(1): 7-12.
- Back S, Liang J (2005) Production of cryptophycin from blue-green algae. Journal of Young Investigator 12:1654-1673.

- Banker R, Carmeli S (1998) Tenucyclamides A– D, Cyclic Hexapeptides from the Cyanobacterium *Nostoc spongiaeforme* var. *tenuis*. *Journal of Natural Products* 61(10):1248-51.
- Basu S, Gledhill M, de Beer D, Matondkar SP, Shaked Y (2019) Colonies of marine cyanobacteria *Trichodesmium* interact with associated bacteria to acquire iron from dust. *Communications Biology* 2(1): 1-8.
- Becher PG, Keller S, Jung G, Süßmuth RD, Jüttner F (2007) Insecticidal activity of 12-epi-hapalindole J isonitrile. *Phytochemistry* 68(19):2493-7.
- Bellahcen TO, AAmiri A, Touam I, Hmimid F, El Amrani A, Cherif A, Cherki M (2020) Evaluation of Moroccan microalgae: *Spirulina platensis* as a potential source of natural antioxidants. *Journal of Complementary and Integrative Medicine* 17(3). <https://doi.org/10.1515/jcim-2019-0036>.
- Bellinger EG, Sigeo DC (2015) *Freshwater algae: identification, enumeration and use as bioindicators*. John Wiley & Sons.
- Bernardini S, Tiezzi A, LaghezzaMasci V, Ovidi E (2018) Natural products for human health: an historical overview of the drug discovery approaches. *Natural Product Research* 32(16): 1926-1950.
- Berry JP, Gantar M, Gawley RE, Wang M, Rein KS (2004) Pharmacology and toxicology of pahayokolide A, a bioactive metabolite from a freshwater species of *Lyngbya* isolated from the Florida Everglades. *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology* 139(4):231-8.
- Bewley CA (2001) Solution structure of a cyanovirin-N: Man α 1-2Man α complex: structural basis for high-affinity carbohydrate-mediated binding to gp120. *Structure* 9(10):931-40.
- Bhadury P, Wright PC (2004) Exploitation of marine algae: biogenic compounds for potential antifouling applications. *Planta* 219(4):561-78.
- Bokesch HR, O'Keefe BR, McKee TC, Pannell LK, Patterson GM, Gardella RS, Sowder RC, Turpin J, Watson K, Buckheit RW, Boyd MR (2003) A potent novel anti-HIV protein from the cultured cyanobacterium *Scytonema varium*. *Biochemistry* 42(9):2578-84.
- Bold HC (1949) The morphology of *Chlamydomonas chlamydogama*, sp. nov. *Bulletin of the Torrey Botanical Club* 1:101-8.
- Bonjouklian R, Moore RE, Patterson GM (1988) Acid-catalyzed reactions of hapalindoles. *The Journal of Organic Chemistry* 53(25):5866-70.
- Boyd MR, Gustafson K, McMahon JB, Shoemaker R (1996) Discovery of cyanovirin-N, a novel HIV-inactivating protein from *Nostoc ellipsosporum* that targets viral gp120. *International Conference on AIDS* 11: 71-71.
- Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. *Antimicrobial Agents and Chemotherapy* 41(7):1521-30.
- Bui HT, Jansen R, Pham HT, Mundt S (2007) Carbamidocyclophanes A– E, Chlorinated Paracyclophanes with Cytotoxic and Antibiotic Activity from the Vietnamese Cyanobacterium *Nostoc* sp. *Journal of Natural Products* 70(4):499-503.
- Cardellina II JH, Kirkup MP, Moore RE, Mynderse JS, Seff K, Simmons CJ (1979a) Hyellazone and chlorohyellazole, two novel carbazoles from the blue-green alga *hyellaea sp.* *Tetrahedron Letters* 20(51):4915-4916.
- Cardellina JH, Marner FJ, Moore RE (1979b) Seaweed dermatitis: structure of lyngbyatoxin A. *Science* 204(4389):193-5.
- Carmichael WW (1992) Cyanobacteria secondary metabolites—the cyanotoxins. *Journal of Applied Bacteriology* 72(6):445-59.
- Carpine R, Sieber S (2021) Antibacterial and antiviral metabolites from cyanobacteria: their application and their impact on human health. *Current Research in Biotechnology* 3: 65-81.
- Chatterjee PM, Tiwari DP, Datta S, Chakrabarty S, Raval R, Dubey AK (2019) Probing into methylene blue interaction with polyglutamic acid: Spectroscopic and molecular dynamics simulation studies. *Asian Journal of Chemistry* 31(9): 1949-1958.
- Chauhan A, Chauhan G, Gupta PC, Goyal P, Kaushik P (2010) In vitro antibacterial evaluation of *Anabaena* sp. against several clinically significant microflora and HPTLC analysis of its active crude extracts. *Indian Journal of Pharmacology* 42(2): 105.
- Chauhan A, Jindal T (2020) *Microbiological Methods for Water, Soil and Air Analysis*. In: *Microbiological Methods for Environment, Food and Pharmaceutical Analysis* 2020, Springer, Cham, Pp. 93-196.
- Chauhan A, Ranjan A, Basniwal RK, Jindal T (2022) Cytotoxic and Antibiotic Properties of Cyanobacterial Extracts. In: Jindal T (eds) *New Frontiers in Environmental Toxicology*. Springer, Cham. https://doi.org/10.1007/978-3-030-72173-2_4.

- Chen X, Smith GD, Waring P (2003) Human cancer cell (Jurkat) killing by the cyanobacterial metabolite calothrixin A. *Journal of Applied Phycology* 15(4):269-77.
- Cheng YI, Chou L, Chiu YF, Hsueh HT, Kuo CH, Chu HA (2020) Comparative genomic analysis of a novel strain of Taiwan hot-spring cyanobacterium *Thermosynechococcus* sp. CL-1. *Frontiers in microbiology* 11: 82.
- Chittapun S, Jonjaroen V, Khumrangsee K, Charoenrat T (2020) C-phycocyanin extraction from two freshwater cyanobacteria by freeze thaw and pulsed electric field techniques to improve extraction efficiency and purity. *Algal Research* 46: 101789.
- Choi H, Engene N, Smith JE, Preskitt LB, Gerwick WH (2010) Crossbyanols A– D, toxic brominated polyphenyl ethers from the Hawaiian bloom-forming Cyanobacterium *Leptolyngbya crossbyana*. *Journal of Natural Products* 73(4):517-22.
- Chorus I, Falconer IR, Salas HJ, Bartram J (2000) Health risks caused by freshwater cyanobacteria in recreational waters. *Journal of Toxicology and Environmental Health Part B: Critical Reviews* 3(4):323-47.
- Chu SP (1942) The influence of the mineral composition of the medium on the growth of planktonic algae: part I. Methods and culture media. *The Journal of Ecology* 1:284-325.
- Dimri AG, Prasad R, Chauhan A, Aggarwal ML, Varma A (2018) Characterization of soil actinomycete isolate against gram-positive and gram-negative food borne bacteria. *Indian Journal of Environmental Protection* 38: 1004-1015.
- Doan NT, Rickards RW, Rothschild JM, Smith GD (2000) Allelopathic actions of the alkaloid 12-epi-hapalindole E isonitrile and calothrixin A from cyanobacteria of the genera *Fischerella* and *Calothrix*. *Journal of Applied Phycology* 12(3):409-16.
- Duy TN, Lam PKS, Shaw GR, Connell DW (2000) Toxicology and Risk Assessment of Freshwater Cyanobacterial (Blue-Green Algal) Toxins in Water. In: Ware GW (Eds.) *Reviews of Environmental Contamination and Toxicology. Reviews of Environmental Contamination and Toxicology*, vol 163. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-6429-1_3.
- El-Sheekh MM, Hassan LH, Morsi HH (2021) Evaluation of antimicrobial activities of blue-green algae-mediated silver and gold nanoparticles. *Rendiconti Lincei. Scienze Fisiche e Naturali* 18:1-3.
- Falch BS, König GM, Wright AD, Sticher O, Angerhofer CK, Pezzuto JM, Bachmann H (1995) Biological activities of cyanobacteria: evaluation of extracts and pure compounds. *Planta Medica* 61(04):321-8.
- Fatima N, Ahmad IZ, Chaudhry H (2017) Alterations in the antibacterial potential of *Synechococcus* spp. PCC7942 under the influence of UV-B radiations on skin pathogens. *Saudi Journal of Biological Sciences* 24(7): 1657-1662.
- Fogg G (1965) *Algal culture and phytoplankton ecology*. University of Wisconsin Press, Madison Pp. 126.
- Gabr GA, El-Sayed SM, Hikal MS (2020) Antioxidant Activities of Phycocyanin: A Bioactive Compound from *Spirulina platensis*. *Journal of Pharmaceutical Research International* 32(2): 73-85.
- Gademann K, Portmann C (2008) Secondary metabolites from cyanobacteria: complex structures and powerful bioactivities. *Current Organic Chemistry* 12(4):326-341.
- Gamal S, Abd El Baky HH, Saleh MA (2020) Egyptian *Arthrospira* phytosterols: production, identification, antioxidant and antiproliferative activities. *Notulae Botanicae Horti Agrobotanici Cluj-Napoca* 48(2): 666-680.
- Gara-Ali M, Zili F, Hosni K, Ouada HB, Ben-Mahrez K (2021) Lipophilic extracts of the thermophilic cyanobacterium *Leptolyngbya* sp. and chlorophyte *Graesiella* sp. and their potential use as food and anticancer agents. *Algal Research* 60: 102511.
- Gerber P, Dutcher JD, Adams EV, Sherman JH (1958) Protective effect of seaweed extracts for chicken embryos infected with influenza B or mumps virus. *Proceedings of the Society for Experimental Biology and Medicine* 99(3): 590-593.
- Gerwick WH, Mrozek C, Moghaddam MF, Agarwal SK (1989) Novel cytotoxic peptides from the tropical marine cyanobacterium *Hormothamnion enteromorphoides* 1. Discovery, isolation and initial chemical and biological characterization of the hormothamnins from wild and cultured material. *Experientia* 45(2):115-21.
- Gheda SF, Ismail GA (2020) Natural products from some soil cyanobacterial extracts with potent antimicrobial, antioxidant and cytotoxic activities. *Anais da Academia Brasileira de Ciências* 92(2):e20190934. doi: 10.1590/0001-3765202020190934.
- Ghosh T, Bhayani K, Paliwal C, Maurya R, Chokshi K, Pancha I, Mishra S (2016) Cyanobacterial pigments as natural anti-hyperglycemic agents: an in vitro study. *Frontiers in Marine Science* 10(3):146.
- Grinberg M, Sarig R, Zaltsman Y, Frumkin D, Grammatikakis N, Reuveny E, Gross A (2002) tBID Homooligomerizes in the

- mitochondrial membrane to induce apoptosis. *Journal of Biological Chemistry* 277(14):12237-45.
- Guerreiro A, Andrade MA, Menezes C, Vilarinho F, Dias E (2020) Antioxidant and Cytoprotective Properties of Cyanobacteria: Potential for Biotechnological Applications. *Toxins* 12(9): 548.
- Gunasekera SP, Ross C, Paul VJ, Matthew S, Luesch H (2008) Dragonamides C and D, linear lipopeptides from the marine cyanobacterium brown *Lyngbya polychroa*. *Journal of Natural products* 71(5):887-90.
- Gustafson KR, Cardellina II JH, Fuller RW, Weislow OS, Kiser RF, Sander KM, Patterson GML, Boyd MR (1989) AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae). *Journal of the National Cancer Institute* 81: 1254-1258.
- Gustafson KR, Sowder R, Henderson L, Pannel L, Cardellina J, McMahon J, Shoemaker R, Boyd M (1996) Sequence determination and chemical characteristics of a novel anti-HIV protein, Cyanovirin-N, isolated from the cyanobacterium *Nostoc ellipsosporum*. *International Controversies on AIDS* 11: 70.
- Hayashi K, Hayashi T, Kojima I (1996) A natural sulfated polysaccharide, calcium spirulan, isolated from *Spirulina platensis*: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. *AIDS Research and Human Retroviruses* 12(15):1463-71.
- Hirata K, Yoshitomi S, Dwi S, Iwabe O, Mahakant A, Polchai J, Miyamoto K (2003) Bioactivities of nostocine A produced by a freshwater cyanobacterium *Nostoc spongiaeforme* TISTR 8169. *Journal of Bioscience and Bioengineering* 95(5):512-7.
- Hokmollahi F, Riahi H, Soltani N, Shariatmadari Z, Hakimi Meybodi MH (2016) A taxonomic study of blue-green algae based on morphological, physiological and molecular characterization in Yazd province terrestrial ecosystems (Iran). *Rostaniha* 16(2): 152-163.
- Hwang P, Hung Y, Tsai Y, Chien SY, Kong Z (2014) The brown seaweed *Sargassum hemiphyllum* exhibits α -amylase and α -glucosidase inhibitory activity and enhances insulin release in vitro. *Cytotechnology* 67: 653-660.
- Inderjit DK, Dakshini KM (1994) Algal allelopathy. *The Botanical Review* 60:182-96.
- Ishibashi M, Moore RE, Patterson GM, Xu C, Clardy J (1986) Scytophycins, cytotoxic and antimycotic agents from the cyanophyte *Scytonema pseudohofmanni*. *The Journal of Organic Chemistry* 51(26):5300-6.
- Ishida K, Matsuda H, Murakami M, Yamaguchi K (1997) Kawaguchipectin B, an antibacterial cyclic undecapeptide from the cyanobacterium *Microcystis aeruginosa*. *Journal of Natural Products* 60(7):724-6.
- Jafari Porzani S, Konur O, Nowruzi B (2021) Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19. *Journal of Biomolecular Structure and Dynamics* 1-17. doi: 10.1080/07391102.2021.1899050.
- Jaki B, Orjala J, Heilmann J, Linden A, Vogler B, Sticher O (2000) Novel Extracellular Diterpenoids with Biological Activity from the Cyanobacterium *Nostoc commune*. *Journal of natural products* 63(3):339-43.
- Jaki B, Zerbe O, Heilmann J, Sticher O (2001) Two novel cyclic peptides with antifungal activity from the cyanobacterium *Tolypothrix byssoidea* (EAWAG 195). *Journal of Natural Products* 64(2):154-8.
- Jaspars M, Lawton LA (1998) Cyanobacteria-a novel source of pharmaceuticals. *Current opinion in Drug Discovery & Development* (1):77-84.
- Jimenez-Lopez C, Pereira AG, Lourenço-Lopes C, Garcia-Oliveira P, Cassani L, Fraga-Corral M, Simal-Gandara J (2021) Main bioactive phenolic compounds in marine algae and their mechanisms of action supporting potential health benefits. *Food Chemistry* 341: 128262.
- Jo SW, Do JM, Na H, Hong JW, Kim IS, Yoon HS (2020) Assessment of biomass potentials of microalgal communities in open pond raceways using mass cultivation. *PeerJ* 8: e9418.
- Jones GJ, Korth W (1995) In situ production of volatile odour compounds by river and reservoir phytoplankton populations in Australia. *Water Science and Technology* 31(11):145-51.
- Kaiwan-arporn P, Hai PD, Thu NT, Annachhatre AP (2012) Cultivation of cyanobacteria for extraction of lipids. *Biomass and Bioenergy* 44: 142-149.
- Kajiyama SI, Kanzaki H, Kawazu K, Kobayashi A (1998) Nostofungicide, an antifungal lipopeptide from the field-grown terrestrial blue-green alga *Nostoc commune*. *Tetrahedron Letters* 39(22):3737-3740.
- Kaushik P, Abhishek C, Pankaj G (2009) Screening of *Lyngbya juncula* for potential antibacterial activity and HPTLC analysis of active methanolic extract. *Journal of Pure and Applied Microbiology* 3(1): 169-174.

- Kaushik P, Chauhan A (2008a) Antibacterial Potential of aqueous and organic extracts of *N. Commune*: A Cyanobacterium. *VEGETOS* 21(1): 77-80.
- Kaushik P, Chauhan A (2008b) In vitro antibacterial activity of laboratory grown culture of *Spirulina platensis*. *Indian Journal of Microbiology* 48(3): 348-352.
- Kaushik P, Goyal P, Chauhan A, Chauhan G (2010) In vitro evaluation of antibacterial potential of dry fruit extracts of *Elettaria cardamomum* Maton (ChhotiElaichi). *Iranian Journal of Pharmaceutical Research* 9(3): 287.
- Kehr JC, Zilliges Y, Springer A, Disney MD, Ratner DD, Bouchier C, Seeberger PH, De Marsac NT, Dittmann E (2006) A mannan binding lectin is involved in cell-cell attachment in a toxic strain of *Microcystis aeruginosa*. *Molecular Microbiology* 59(3):893-906.
- Khatoun H, Leong LK, Rahman NA, Mian S, Begum H, Banerjee S, Endut A (2018) Effects of different light source and media on growth and production of phycobiliprotein from freshwater cyanobacteria. *Bioresource Technology* 249: 652-658.
- Larsen LK, Moore RE, Patterson GM (1994) β -Carbolines from the blue-green alga *Dichothrix baueriana*. *Journal of Natural Products* 57(3):419-21.
- Lau AF, Siedlecki J, Anleitner J, Patterson GM, Caplan FR, Moore RE (1993) Inhibition of reverse transcriptase activity by extracts of cultured blue-green algae (cyanophyta). *Planta Medica* 59: 148-151.
- Li LY, Wu W, Chen S, Gu JW, Li XL, Song HJ, Du F, Wang G, Zhong CQ, Wang XY, Chen Y, Shah R, Yang HM, Cai Q (2020) Digestive system involvement of novel coronavirus infection: Prevention and control infection from a gastroenterology perspective. *Journal of Digestive Diseases* 21(4):199–204.<https://doi.org/10.1111/1751-2980.12862>
- Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, Lee PP (2006) Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. *Antimicrobial Agents and Chemotherapy* 50(10):3250-3259.
- Loya S, Reshef V, Mizrrachi E, Silberstein C, Rachamim Y, Carmeli S, Hizi A (1998) The inhibition of the reverse transcriptase of HIV-1 by the natural sulfoglycolipids from cyanobacteria: contribution of different moieties to their high potency. *Journal of Natural Product* 61: 891-895.
- Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH (2001) Isolation of dolastatin 10 from the marine cyanobacterium *Symploca species* VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. *Journal of Natural Products* 64(7):907-10.
- MacMillan JB, Ernst-Russell MA, De Ropp JS, Molinski TF (2002) Lobocyclamides A– C, Lipopeptides from a cryptic cyanobacterial mat containing *Lyngbya confervoides*. *The Journal of Organic Chemistry* 67(23):8210-5.
- MacMillan JB, Molinski TF (2005) Majusculic acid, a brominated cyclopropyl fatty acid from a marine cyanobacterial mat assemblage. *Journal of Natural Products* 68(4):604-6.
- Marrez DA, Sultan YY (2016) Antifungal activity of the cyanobacterium *Microcystis aeruginosa* against mycotoxigenic fungi. *Journal of Applied Pharmaceutical Science* 6(11): 191-198.
- Mason CP, Edwards KR, Carlson RE, Pignatello J, Gleason FK, Wood JM (1982) Isolation of chlorine-containing antibiotic from the freshwater cyanobacterium *Scytonema hofmanni*. *Science* 215(4531):400-2.
- Matern U, Oberer L, Falchetto RA, Erhard M, König WA, Herdman M, Weckesser J (2001) Scytolin A and B, cyclic depsipeptides from axenic cultures of *Scytonema hofmanni* PCC 7110. *Phytochemistry* 58(7):1087-95.
- Mathew B, Sankaranarayanan R, Nair PP, Varghese C, Somanathan T, Amma BP, Amma NS, Nair MK (1995) Evaluation of chemoprevention of oral cancer with *Spirulina fusiformis*. *Nutrition and Cancer* 24: 197-202
- Medina RA, Goeger DE, Hills P, Mooberry SL, Huang N, Romero LI, Ortega-Barría E, Gerwick WH, McPhail KL (2008) Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium *Leptolyngbya* sp. *Journal of the American Chemical Society* 130(20):6324-5.
- Metting B, Pyne JW (1986) Biologically active compounds from microalgae. *Enzyme and Microbial Technology* 8(7):386-94.
- Mishima T, Murata J, Toyoshima M, Fujii H, Nakajima M, Hayashi T, Kato T, Saiki I (1998) Inhibition of tumor invasion and metastasis by calciumspirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, *Spirulina platensis*. *Clinical & Experimental Metastasis* 16(6):541-550.
- Mo S, Kronic A, Chlipala G, Orjala J (2009) Antimicrobial ambigua isonitriles from the cyanobacterium *Fischerella ambigua*. *Journal of Natural Products* 72(5):894-9.

- Moon SS, Chen JL, Moore RE, Patterson GM (1992) Calophycin, a fungicidal cyclic decapeptide from the terrestrial blue-green alga *Calothrix fusca*. The Journal of Organic Chemistry 57(4):1097-103.
- Moore RE (1982) Toxins, anticancer agents, and tumor promoters from marine prokaryotes. Pure and Applied Chemistry 54(10):1919-34.
- Moore RE, Patterson GM, Carmichael WW (1988) New pharmaceuticals from cultured blue-green algae. Biomedical Importance of Marine Organisms 13:143-50.
- Moore RE, Yang XQ, Patterson GM (1987) Fontonamide and anhydrohapaloxindole A, two new alkaloids from the blue-green alga *Hapalosiphon fontinalis*. The Journal of Organic Chemistry 52(17):3773-3777.
- Müller D, Krick A, Kehraus S, Mehner C, Hart M, Küpper FC, Saxena K, Prinz H, Schwalbe H, Janning P, Waldmann H (2006) Brunsvicamides A– C: Sponge-Related Cyanobacterial Peptides with *Mycobacterium tuberculosis* Protein Tyrosine Phosphatase Inhibitory Activity. Journal of Medicinal Chemistry 49(16):4871-8.
- Mundt S, Kreitlow S, Jansen R (2003) Fatty acids with antibacterial activity from the cyanobacterium *Oscillatoria redekei* HUB 051. Journal of Applied Phycology 15(2):263-7.
- Nagatsu A, Kajitani H, Sakakibara J, Muscoride A (1995) A new oxazole peptide alkaloid from freshwater cyanobacterium *Nostoc muscorum*. Tetrahedron Letters 36(23):4097-100.
- Nainangu P, Antonyraj APM, Subramanian K, Kaliyaperumal S, Gopal S, Renuka PS (2020) In vitro screening of antimicrobial, antioxidant, cytotoxic activities, and characterization of bioactive substances from freshwater cyanobacteria *Oscillatoria* sp. SSCM01 and *Phormidium* sp. SSCM02. Biocatalysis and Agricultural Biotechnology 29: 101772.
- Natarajan C, Prasanna R, Gupta V, Dureja P, Nain L (2012) Characterization of the fungicidal activity of *Calothrix elenkinii* using chemical methods and microscopy. Applied Biochemistry and Microbiology 48(1):51-57.
- Neuhof T, Schmieder P, Preussel K, Dieckmann R, Pham H, Bartl F, von Döhren H (2005) Hassallidin A, a glycosylated lipopeptide with antifungal activity from the cyanobacterium *Hassallia* sp. Journal of Natural Products 68(5):695-700.
- Niveshika, Verma E, Mishra AK, Singh AK, Singh VK (2016) Structural elucidation and molecular docking of a novel antibiotic compound from cyanobacterium *Nostoc* sp. MGL001. Frontiers in microbiology 7:1899.
- Padmini N, Ajilda AA, Prabakaran P, Sivakumar N, Selvakumar G (2021) Efficacy of marine cyanobacterium *Oxynemathia* sp. ALU PBC5 against multi drug resistant Gram negative pathogens. Journal of Applied Microbiology 130(1):50-60.
- Petersen LE, Kellermann MY, Schupp PJ (2020) Secondary metabolites of marine microbes: From natural products chemistry to chemical ecology. Youmares 9-The Oceans: Our Research, Our Future 159.
- Ploutno A, Carmeli S (2000) Nostocyclone A, a novel antimicrobial cyclophane from the cyanobacterium *Nostoc* sp. Journal of Natural Products 63(11):1524-6.
- Pratt R, Daniels TC, Eiler JJ, Gunnison JB, Kumler WD, Oneto JF, Strait LA, Spoehr HA, Hardin GJ, Milner HW, Smith JH (1944) Chlorellin, an antibacterial substance from *Chlorella*. Science 99 (2574):351-352.
- Priatni S, Budiwati TA, Ratnaningrum D, Kosasih W, Andryani R, Susanti H, Susilaningih W (2016) Antidiabetic screening of some Indonesian marine cyanobacteria collection. Biodiversitas 17(2): 641–646.
- Pringsheim E (1946) Pure Cultures of Algae. Cambridge University Press London Pp. 119 .
- Prinsep MR, Moore RE, Levine IA, Patterson GM (1992) Westiellamide, a biastamide-related cyclic peptide from the blue-green alga *Westiellopsis prolifica*. Journal of Natural Products 55(1):140-2.
- Radkova M, Stefanova K, Uzunov B, Gärtner G, Stoyneva-Gärtner M (2020) Morphological and molecular identification of microcystin-producing cyanobacteria in nine shallow Bulgarian water bodies. Toxins 12(1): 39.
- Radzi R, Muangmai N, Broady P, Wan Omar WM, Lavoue S, Convey P, Merican F (2019) *Nodosilineasigniensis* sp. Nov. (Leptolyngbyaceae, Synechococcales), a new terrestrial cyanobacterium isolated from mats collected on Signy Island, South Orkney Islands, Antarctica. PloSone 14(11): e0224395.
- Raveh A, Carmeli S (2007) Antimicrobial ambigues from the cyanobacterium *Fischerella* sp. collected in Israel. Journal of Natural Products 70(2):196-201.
- Rego A, Raio F, Martins TP, Ribeiro H, Sousa AG, Séneca J, Magalhães C (2019) Actinobacteria and cyanobacteria diversity in terrestrial antarctic microenvironments evaluated by culture-

- dependent and independent methods. *Frontiers in Microbiology* 10: 1018.
- Reshef V, Mizrahi E, Marezki T, Silberstein C, Loya S, Hizi A, Carmeli S (1997) New acetylated sulfoglycolipids and digalactolipids and related known glycolipids from cyanobacteria with potential to inhibit the reverse transcriptase of HIV-1. *Journal of Natural Products* 60: 1251-1260.
- Riba M, Kiss-Szikszai A, Gonda S, Parizsa P, Deák B, Török P, Vasas G (2020) Chemotyping of terrestrial Nostoc-like isolates from alkali grassland areas by non-targeted peptide analysis. *Algal Research* 46: 101798.
- Rippka R, Deruelles J, Waterbury JB, Herdman M, Stanier RY (1979) Generic assignments, strain histories and properties of pure cultures of cyanobacteria. *Microbiology* 111: 1- 61.
- Romay C, Ledon N, Genzalez R (1999) Phycocyanin extract reduces leukotriene B4 levels in arachidonic acid-induced mouse-ear inflammation test. *Journal of Pharmacy and Pharmacology* 51(5): 641-642.
- Safari R, Raftani Amiri Z, Esmaeilzadeh Kenari R (2020) Antioxidant and antibacterial activities of C-phycocyanin from common name *Spirulina platensis*. *Iranian Journal of Fisheries Sciences* 19(4): 1911-1927.
- Sami N, Ahmad R, Fatma T (2021) Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-2 *Biomedical Journal* 44(1) 54-62.
- Saurav K, Macho M, Kust A, Delawská K, Hájek J, Hrouzek P (2019) Antimicrobial activity and bioactive profiling of heterocytous cyanobacterial strains using MS/MS-based molecular networking. *Folia Microbiologica* 64(5): 645-654.
- Schaeffer DJ, Krylov VS (2000) Anti-HIV activity of extracts and compounds from algae and cyanobacteria. *Ecotoxicology and Environmental safety* 45(3):208-27.
- Schwartz J, Shklar G, Reid S, and Trickler D (1988) Prevention of experimental oral cancer by extracts of *Spirulina-Dunaliella* algae. *Nutrition and Cancer* 11 (2); 127-134.
- Seddek NH, Fawzy MA, El-Said WA, Ahmed MMR (2019) Evaluation of antimicrobial, antioxidant and cytotoxic activities and characterization of bioactive substances from freshwater blue-green algae. *Global Nest Journal* 21(3): 328-336.
- Senousy HH, Abd Ellatif S, Ali S (2020) Assessment of the antioxidant and anticancer potential of different isolated strains of cyanobacteria and microalgae from soil and agriculture drain water. *Environmental Science and Pollution Research* 27: 18463–18474.
- Shi SR, Cote RJ, Taylor CR (1999) Standardization and further development of antigen retrieval immunohistochemistry: strategies and future goals. *Journal of Histotechnology* 22(3):177-92.
- Shishido TK, Popin RV, Jokela J, Wahlsten M, Fiore MF, Fewer DP, Herfindal L, Sivonen K (2020) Dereplication of natural products with antimicrobial and anticancer activity from Brazilian cyanobacteria. *Toxins* 12(1):12.DOI: 10.3390/toxins12010012.
- Singh IP, Milligan KE, Gerwick WH (1999) Tanikolide, a toxic and antifungal lactone from the marine cyanobacterium *Lyngbya m. ajuscula*. *Journal of Natural Products* 62(9):1333-5.
- Singh SM, Elster JOSEF (2007) Cyanobacteria in Antarctic lake environments. In: *Algae and cyanobacteria in extreme environments*. Springer, Dordrecht Pp. 303-320.
- Singh U, Singh AK, Asthana RK (2021a) Bioactive molecules from microalgae and constraints in commercialization. *Natural Bioactive Compounds* Pp. 143-164.
- Singh U, Singh P, Singh AK, Kumar D, Tilak R, Shrivastava SK, Asthana RK (2021b) Identification of antifungal and antibacterial biomolecules from a cyanobacterium, *Arthrospira platensis*. *Algal Research* 54:102215.
- Smetana S, Sandmann M, Rohn S, Pleissner D, Heinz V (2017) Autotrophic and heterotrophic microalgae and cyanobacteria cultivation for food and feed: life cycle assessment. *Bioresource Technology* 245: 162-170.
- Spoehr HA, Milner HW (1949) The chemical composition of *Chlorella*; effect of environmental conditions. *Plant physiology* 24(1):120.
- Sridhar K, Inbaraj BS, Chen BH(2021) Recent developments on production, purification and biological activity of marine peptides. *Food Research International* 147: p.110468.
- Srivastava VC, Manderson GJ, Bhamidimarri R (1999) Inhibitory metabolites production by the cyanobacterium *Fischerellamuscicola*. *Microbiological Research* 153(4):309-17.
- Stanier G (1988) Fine structure of cyanobacteria. *Methods in Enzymology* 167:157-172.
- Stevenson CS, Capper EA, Roshak AK, Marquez B, Eichman C, Jackson JR, Mattern M, Gerwick WH, Jacobs RS, Marshall LA (2002) The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore.

- Journal of Pharmacology and Experimental Therapeutics 303(2):858-66.
- Stratmann K, Moore RE, Bonjouklian R, Deeter JB, Patterson GM, Shaffer S, Smith CD, Smitka TA (1994) Welwitindolinones, unusual alkaloids from the blue-green algae *Hapalosiphon welwitschii* and *Westiellaintricata*. Relationship to fischerindoles and hapalinodoles. Journal of the American Chemical Society 116(22):9935-9942.
- Sturdy M, Kronic A, Cho S, Franzblau S, Orjala J (2010) Eucapsitrone, an anti-*Mycobacterium tuberculosis* anthraquinone derivative from the cultured freshwater cyanobacterium *Eucapsis* sp. Journal of natural products 73(8):1441-3.
- Tang J, Jiang D, Luo Y, Liang Y, Li L, Shah MMR, Daroch M (2018) Potential new genera of cyanobacterial strains isolated from thermal springs of western Sichuan, China. Algal Research 31: 14-20.
- Thajuddin N, Subramanian G (2005) Cyanobacterial biodiversity and potential applications in biotechnology. Current Science 10:47-57.
- Tokuda H, Nishino H, Shirahashi H, Murakami N, Nagatsu A, Sakakibara J (1996) Inhibition of 12-O-tetradecanoylphorbol-13-acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium *Phormidium tenue*. Cancer Letter 104: 91-95.
- Trimurtulu G, Ohtani I, Patterson GM, Moore RE, Corbett TH, Valeriote FA, Demchik L (1994) Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga *Nostoc* sp. strain GSV 224. Journal of the American Chemical Society 116(11):4729-37.
- Troschl C, Fritz I, Sodnikar K, Drosig B (2017) Contaminations in mass cultivation of cyanobacteria: Highly resilient *Colpoda steinii* leads to rapid crash of *Synechocystis* sp. cultures and is inhibited by partially anoxic conditions. Algal research 28: 229-234.
- Uma VS, Gnanasekaran D, Lakshmanan U, Dharmar P (2020) Survey and isolation of marine cyanobacteria from eastern coast of India as a biodiesel feedstock. Biocatalysis and Agricultural Biotechnology 24: 101541.
- Vanlalveni C, Rajkumari K, Biswas A, Adhikari PP, Lalfakzuala R, Rokhum L (2018) Green synthesis of silver nanoparticles using *Nostoc linckia* and its antimicrobial activity: a novel biological approach. BioNanoScience 8(2): 624-631.
- Vasudevan S, Arulmoorthy MP, Suresh R (2020) Isolation, purification and structural elucidation of secondary metabolites from *Microcystis aeruginosa* bloom from *Muttukadu estuary* and its in vitro antibacterial, antioxidant and anticancer potency. South African Journal of Botany 132: 59-67.
- Verma E, Mishra AK, Singh AK, Singh VK (2016) Structural elucidation and molecular docking of a novel antibiotic compound from cyanobacterium *Nostoc* sp. MGL001. Frontiers in Microbiology 29(7):1899.
- Volk RB, Furkert FH (2006) Antialgal, antibacterial and antifungal activity of two metabolites produced and excreted by cyanobacteria during growth. Microbiological Research 161(2):180-6.
- WHO (2017) Global priority list of Antibiotic resistant bacteria to guide research discovery and developments of new antibiotics.
- Wright AD, Papendorf O, König GM (2005) Ambigol C and 2, 4-Dichlorobenzoic Acid, Natural Products Produced by the Terrestrial Cyanobacterium *Fischerella ambigua*. Journal of Natural Products 68(3):459-461.
- Xiong C, O'Keefe BR, Byrd RA, McMahon JB (2006) Potent anti-HIV activity of scytovirin domain 1 peptide. Peptides 27(7):1668-75.
- Xu HL, Kitajim C, Ito H, Miyazaki T, Bab M, Okuyama T (2012) Antidiabetic effect of polyphenols from brown alga *Ecklonia kurome* in genetically diabetic KK-Ay mice, Pharmaceutical Biology 50: 393-400.
- Yamaguchi M, Ogawa T, Muramoto K, Kamio Y, Jimbo M, Kamiya (1999) Isolation and characterization of a mannan-binding lectin from the freshwater cyanobacterium (blue-green algae) *Microcystis viridis*. Biochemical and Biophysical Research Communications 265(3):703-8.
- Yoon SH, Lee YM, Kim JE, Lee SH, Lee JH, Kim JY, Jung KH, Shin YC, Keasling JD, Kim SW (2006) Enhanced lycopene production in *Escherichia coli* engineered to synthesize isopentenyl diphosphate and dimethylallyl diphosphate from mevalonate. Biotechnology and Bioengineering 94(6):1025-32.
- Yücer TD, Beyatlı Y, Pabuçcu K (2018) The antiproliferative and antimicrobial effects of cultivated *Anabaena circinalis* Rabenhorts ex Bornet and Flahault and *Nostoc entophyllum* Bornet and Flahault. Tropical Journal of Pharmaceutical Research 17(8): 1571-1577.
- Zaki S, Merican F, Muangmai N, Convey P, Broady P (2020). Discovery of microcystin-producing *Anagnostidinema pseudacutissimum* from cryopreserved Antarctic cyanobacterial mats. Harmful algae 93: 101800.